• Niraparib Plus Abiraterone/Prednisone Maintains rPFS Benefit in HRR Gene–Altered mCRPC.
    • Wrigley N.
    • OncLive. 2023 Feb 17.

    Related:

    •• Identifier: NCT03748641: A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE). (ClinicalTrials.gov . Accessed 2023 Feb 18.)

    • Drugmakers Pushing Frontline PARP Inhibitor Combos for All mCRPC Patients Amid Oncologists' Concerns.
    • Hopkins C.
    • Precision Oncology News. 2023 Feb 17.
    • Press
    • Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
    • Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH; TRITON3 Investigators.
    • N Engl J Med. 2023 Feb 16. doi: 10.1056/NEJMoa2214676. Epub ahead of print.

    Related:

    •• Identifier: NCT02975934: A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3). (ClinicalTrials.gov . Accessed 2023 Feb 16.)

    •• Research news: Rucaparib Bests Physician's Choice for BRCA+ mCRPC. (OncLive)

    • Prostate cancer and novel pharmacological treatment options - what's new for 2022?
    • Marchetti A, Tassinari E, Rosellini M, Rizzo A, Massari F, Mollica V.
    • Expert Rev Clin Pharmacol. 2023 Feb 15. doi: 10.1080/17512433.2023.2181783. Epub ahead of print.
    • Review
    • A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE).
    • Pan E, Xie W, Ajmera A, Araneta A, Jamieson C, Folefac E, Hussain A, Kyriakopoulos CE, Olson A, Parikh M, Parikh R, Saraiya B, Ivy SP, Van Allen EM, Lindeman NI, Kochupurakkal BS, Shapiro GI, McKay RR.
    • Mol Cancer Ther. 2023 Feb 10:MCT-22-0583. doi: 10.1158/1535-7163.MCT-22-0583. Epub ahead of print.
    • Dr. Choudhury on the Potential Benefit of PARP Inhibitor Use in mCRPC.
    • Choudhury AD.
    • OncLive. OncLive TV. 2023 Feb 8.
    • Mutation Status Drives PARP Inhibitor Investigation and Treatment in mCRPC.
    • Wahner A.
    • OncLive. 2023 Feb 1.
    • Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study.
    • Yang ES, Halabi S, Rothe M, Garrett-Mayer E, Mangat PK, Pisick E, Dib E, Burgess EF, Zakem M, Rohatgi N, Bilen MA, O'Lone R, Grantham GN, Schilsky RL.
    • JCO Precis Oncol. 2023 Feb;7:e2200505. doi: 10.1200/PO.22.00505.

    Related:

    •• Identifier: NCT02693535: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR). (ClinicalTrials.gov . Accessed 2023 Feb 8.)

    • A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors.
    • Gao B, Voskoboynik M, Cooper A, Wilkinson K, Hoon S, Hsieh CY, Cai S, Tian YE, Bao J, Ma N, Wang C, Zhang M, Li B, Guo M, Zhou R, Wang X, Xu C, de Souza P.
    • Cancer. 2023 Jan 31. doi: 10.1002/cncr.34662. Epub ahead of print.

    Related:

    •• Identifier: NCT03507543: The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    • Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review.
    • Hatano K, Nonomura N.
    • World J Mens Health. 2023 Jan 27. doi: 10.5534/wjmh.220200. Epub ahead of print.
    • Emerging systemic treatment for metastatic castration-resistant prostate cancer: a review of recent randomized controlled trials.
    • Yanagisawa T, Kawada T, Rajwa P, Kimura T, Shariat SF.
    • Curr Opin Urol. 2023 Jan 25. doi: 10.1097/MOU.0000000000001080. Epub ahead of print.
    • Review
    • Androgen Deprivation Freezes Hormone-Sensitive Prostate Cancer Cells in a Reversible, Genetically Unstable Quasi-Apoptotic State, Bursting into Full Apoptosis upon Poly(ADP-ribose) Polymerase Inhibition.
    • Pelliccia A, Capradossi F, Corsi F, Tarquini GD, Bruni E, Reichle A, Torino F, Ghibelli L.
    • Int J Mol Sci. 2023 Jan 20;24(3):2040. doi: 10.3390/ijms24032040.
    • Response to bipolar androgen therapy and PD-1 inhibition in a patient with metastatic castration-resistant prostate cancer and a germline CHEK2 mutation.
    • Berger BT, Labriola MK, Antonarakis ES, Armstrong AJ.
    • BMJ Case Rep. 2023 Jan 18;16(1):e251320. doi: 10.1136/bcr-2022-251320.
    • Case report
    • CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.
    • Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, Miao C, Feng C, Gui B, Sztupinszki Z, Simoneau A, Xie N, Fazli L, Dong X, Azuma H, Choudhury AD, Mouw KW, Szallasi Z, Zou L, Kibel AS, Jia L.
    • Nat Commun. 2023 Jan 17;14(1):252. doi: 10.1038/s41467-023-35880-y.
    • Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer.
    • Nukaya T, Sumitomo M, Sugihara E, Takeda M, Nohara S, Tanishima S, Takenaka M, Zennami K, Takahara K, Shiroki R, Saya H.
    • Cancer Med. 2023 Jan 16. doi: 10.1002/cam4.5617. Epub ahead of print.
    • DNA Repair Deficiency as Circulating Biomarker in Prostate Cancer.
    • Roviello G, Generali D, Gatti M, Riboli B, Paganini L, Nesi G, Catalano M.
    • Front Oncol. 2023 Jan 12;12:1115241. doi: 10.3389/fonc.2023.1115241.
    • Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches.
    • Posdzich P, Darr C, Hilser T, Wahl M, Herrmann K, Hadaschik B, Grünwald V.
    • Cancers (Basel). 2023 Jan 11;15(2):461. doi: 10.3390/cancers15020461.
    • Novel Combination Regimens Strengthen and Expand Treatment Paradigm for Genitourinary Cancers.
    • Flaherty C, Dorff TB.
    • OncLive. 2023 Jan 10.
    • Dr. Dorff on the Investigation of PARP Inhibitors in mCRPC.
    • Dorff TB.
    • OncLive. OncLive TV. 2023 Jan 10.
    • Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
    • Qi F, Xu Z, Zou Q.
    • Eur Urol. 2023 Jan 3:S0302-2838(22)02873-1. doi: 10.1016/j.eururo.2022.12.024. Epub ahead of print.
    • Letter

    Related:

    •• Original research:

    Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.

    •• Reply:

    Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.

    • Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    • Herzog TJ, Vergote I, Gomella LG, Milenkova T, French T, Tonikian R, Poehlein C, Hussain M.
    • Eur J Cancer. 2022 Dec 21 [2023 Jan 1];179:136-146. doi: 10.1016/j.ejca.2022.10.021. Epub ahead of print.
    • Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin.
    • Miyazawa Y, Shimizu T, Sekine Y, Arai S, Ohtsu A, Fujizuka Y, Nomura M, Koike H, Matsui H, Suzuki K.
    • IJU Case Rep. 2022 Oct 9 [eCollection 2023 Jan];6(1):37-40. doi: 10.1002/iju5.12543.

    Related:

    •• Letter:

    Editorial Comment on "Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin".

    • How the Analysis of the Pathogenetic Variants of DDR Genes Will Change the Management of Prostate Cancer Patients.
    • Sciarra A, Frisenda M, Bevilacqua G, Gentilucci A, Cattarino S, Mariotti G, Del Giudice F, Di Pierro GB, Viscuso P, Casale P, I. Chung BI, Autorino R, Crivellaro S, Salciccia S.
    • Int J Mol Sci. 2022 Dec 30;24(1):674. doi: 10.3390/ijms24010674.
    • Combination with vorinostat enhances the antitumor activity of cisplatin in castration-resistant prostate cancer by inhibiting DNA damage repair pathway and detoxification of GSH.
    • Chang T, Lian Z, Ma S, Liang Z, Ma X, Wen X, Wang Y, Liu R.
    • Prostate. 2022 Dec 28. doi: 10.1002/pros.24479. Epub ahead of print.
    • LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer.
    • [No author given]
    • Merck.com . News releases. 2022 Dec 21.

    Related:

    •• Press release: Lynparza in combination with abiraterone approved in the EU as 1st-line treatment for patients with metastatic castration-resistant prostate cancer. (AstraZeneca. Media.)

    • European Commission Approves Olaparib Plus Abiraterone and Prednisone/Prednisolone for mCRPC.
    • Ryan C.
    • OncLive. 2022 Dec 21.
    • Update on US regulatory priority review of Lynparza in combination with abiraterone in metastatic castration-resistant prostate cancer.
    • Kemp A.
    • AstraZeneca. Media. Press Releases. 2022 Dec 15.
    • FDA Delays PDUFA Hearing for Olaparib/Abiraterone Combo in mCRPC.
    • Harris J.
    • OncLive. 2022 Dec 15.

    Related:

    •• Identifier: NCT03732820: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer. (ClinicalTrials.gov . Accessed 2022 Dec 15.)

    • Cost-effectiveness of PARP inhibitors in malignancies: A systematic review.
    • Ding H, He C, Tong Y, Fang Q, Mi X, Chen L, Xin W, Fang L.
    • PLoS One. 2022 Dec 15;17(12):e0279286. doi: 10.1371/journal.pone.0279286.
    • Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients-a systematic review and meta-analysis.
    • Fazekas T, Széles ÁD, Teutsch B, Csizmarik A, Vékony B, Váradi A, Kói T, Lang Z, Ács N, Kopa Z, Hegyi P, Hadaschik B, Grünwald V, Nyirády P, Szarvas T.
    • Prostate Cancer Prostatic Dis. 2022 Dec 12. doi: 10.1038/s41391-022-00626-2. Epub ahead of print.
    • BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.
    • Darabi S, Braxton DR, Xiu J, Carneiro BA, Swensen J, Antonarakis ES, Liu SV, McKay RR, Spetzler D, El-Deiry WS, Demeure MJ.
    • Medicina (Kaunas). 2022 Dec 10;58(12):1818. doi: 10.3390/medicina58121818.
    • Dr. George on the Use of Niraparib for Patients With BRCA and ATM Mutations in mCRPC.
    • George DJ.
    • OncLive. OncLive TV. 2022 Dec 9.

    Related:

    •• Identifier: NCT02854436: An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies (Galahad). (ClinicalTrials.gov . Accessed 2022 Dec 10.)

    • Detection of BRCA1, and BRCA2 in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting.
    • McFarland TR, Thomas VM, Nussenzveig R, Gebrael G, Sayegh N, Tripathi N, Sahu KK, Goel D, Maughan BL, Sirohi D, Agarwal N, Swami U.
    • Biomedicines. 2022 Dec 7;10(12):3170. doi: 10.3390/biomedicines10123170.
    • The potential of PARP inhibitors in targeted cancer therapy and immunotherapy.
    • Hunia J, Gawalski K, Szredzka A, Suskiewicz MJ, Nowis D.
    • Front Mol Biosci. 2022 Dec 1;9:1073797. doi: 10.3389/fmolb.2022.1073797.
    • Management of patients with advanced prostate cancer in Japan: 'real-world' consideration of the results from the Advanced Prostate Cancer Consensus Conference.
    • Fujita K, Suzuki H, Hinata N, Miura Y, Edamura K, Tabata KI, Arai G, Matsubara N, Yasumizu Y, Kosaka T, Oya M, Sugimoto M.
    • Transl Androl Urol. 2022 Dec;11(12):1771-1785. doi: 10.21037/tau-22-396.

    Related:

    •• Commentary:

    Assessment of real-world application of advanced prostate cancer management in Japan.

    • Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
    • Inderjeeth AJ, Topp M, Sanij E, Castro E, Sandhu S.
    • Cancers (Basel). 2022 Nov 30;14(23):5922. doi: 10.3390/cancers14235922.
    • 3D CRISPR screen in prostate cancer cells reveals PARP inhibitor sensitization through TBL1XR1-SMC3 interaction.
    • Zhang H, Gao H, Gu Y, John A, Wei L, Minhong Huang M, Yu J, Adeosun AA, Weinshilboum RM, Wang L.
    • Front Oncol. 2022 Nov 29;12:999302. doi: 10.3389/fonc.2022.999302.
    • Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine.
    • Marino F, Totaro A, Gandi C, Bientinesi R, Moretto S, Gavi F, Pierconti F, Iacovelli R, Bassi P, Sacco E.
    • Prostate Cancer Prostatic Dis. 2022 Nov 24. doi: 10.1038/s41391-022-00609-3. Epub ahead of print.
    • Review
    • Precision Medicine Provides Continued Benefit in mCRPC.
    • George DJ, Scott R.
    • OncLive. 2022 Nov 21.
    • Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
    • Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA.
    • JAMA Oncol. 2022 Nov 17. doi: 10.1001/jamaoncol.2022.5218. Epub ahead of print.

    Related:

    •• Identifier: NCT03565991: Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Nov 19.)

    •• Commentary:

    Combining PARP Inhibitor With Immunotherapy-Does the Promise of Preclinical Data Translate to Clinic?

    • Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
    • Su CT, Nizialek E, Berchuck JE, Vlachostergios PJ, Ashkar R, Sokolova A, Barata PC, Aggarwal RR, McKay RR, Agarwal N, McClure HM, Nafissi N, Bryce AH, Sartor O, Sayegh N, Cheng HH, Adra N, Sternberg CN, Taplin ME, Cieslik M, Alva AS, Antonarakis ES.
    • Prostate. 2022 Nov 16. doi: 10.1002/pros.24454. Epub ahead of print.
    • Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations.
    • Wu MS, Goldberg H.
    • Cancer Manag Res. 2022 Nov 15;14:3159-3174. doi: 10.2147/CMAR.S353411.
    • Stellenwert der genetischen Testung beim Prostatakarzinom [Importance of genetic testing in prostate cancer].
    • Steinkellner L, Luger F, Loidl W.
    • Urologie. 2022 Nov 15. German. doi: 10.1007/s00120-022-01977-3. Epub ahead of print.
    • Review. [Article in German]
    • Genetic Testing Proves Significant in Identifying Somatic and Germline Mutations in Prostate Cancer.
    • Hollasch M, Antonarakis ES.
    • OncLive. 2022 Nov 11.
    • Prostate Cancer Has High Rate of Actionable Mutations, Underscoring Need for Testing.
    • Rosa K, Antonarakis ES.
    • OncLive. 2022 Nov 11.
    • Dr. Antonarakis on Therapeutic Agents for Select Patients With mCRPC.
    • Antonarakis ES.
    • OncLive. OncLive TV. 2022 Nov 11.
    • The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study.
    • Uemura H, Oya M, Kamoto T, Sugimoto M, Shinozaki K, Morita K, Koto R, Takahashi M, Nii M, Shin E, Nonomura N.
    • Cancer Med. 2022 Nov 10. doi: 10.1002/cam4.5333. Epub ahead of print.
    • Sequential Olaparib, Adavosertib Administration Overcomes Concurrent Use Toxicity Problems.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Nov 2.
    • Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 or ATM Alterations Identified by Testing Circulating Tumor DNA.
    • Matsubara N, de Bono J, Olmos D, Procopio G, Kawakami S, Ürün Y, van Alphen R, Flechon A, Carducci MA, Choi YD, Hotte SJ, Korbenfeld E, Kramer G, Agarwal N, Chi KN, Dearden S, Gresty C, Kang J, Poehlein C, Harrington EA, Hussain M.
    • Clin Cancer Res. 2022 Nov 1:CCR-21-3577. doi: 10.1158/1078-0432.CCR-21-3577. Epub ahead of print.

    Related:

    •• Identifier: NCT02987543: Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study). (ClinicalTrials.gov . Accessed 2022 Nov 5.)

    • A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy.
    • Naiki T, Naiki-Ito A, Kawai T, Komatsu H, Nishikawa R, Gonda M, Aoki M, Sugiyama Y, Tasaki Y, Yasui T.
    • IJU Case Rep. 2022 Jun 29 [eCollection 2022 Nov];5(6):431-435. doi: 10.1002/iju5.12501.

    Related:

    •• Commentary:

    Editorial Comment from Dr Sekino and Dr Hinata to A case of metastatic treatment emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy.

    •• Commentary:

    Editorial Comment from Dr Kato to A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation by liver biopsy.

    • Prostate cancer recurring as small-cell carcinoma with a BRCA2 somatic mutation.
    • Yabusaki R, Yoshimura K, Taku K, Suzuki M.
    • IJU Case Rep. 2022 Aug 12 [eCollection 2022 Nov];5(6):489-492. doi: 10.1002/iju5.12523.
    • PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Whom to Treat?
    • Loguidice CT.
    • OncLive. 2022 Oct 28.
    • Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study.
    • Rodriguez-Vida A, Maroto P, Font A, Martin C, Mellado B, Corbera A, Orrillo M, Reig O, Querol R, Rios-Hoyo A, Cano L, Alonso J, Martinez G, Galtes S, Taus A, Martinez-Garcia M, Juanpere N, Juan O, Bellmunt J.
    • Br J Cancer. 2022 Oct 26. doi: 10.1038/s41416-022-01991-4. Epub ahead of print.
    • The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations.
    • Teply BA, Antonarakis ES.
    • Expert Rev Clin Pharmacol. 2022 Oct 26. doi: 10.1080/17512433.2022.2140656. Epub ahead of print.
    • Review
    • Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients.
    • Zhang D, Xu X, Wei Y, Chen X, Li G, Lu Z, Zhang X, Ren X, Wang S, Qin C.
    • Cancer Control. 2022 Jan-Dec [2022 Oct 25];29:10732748221129451. doi: 10.1177/10732748221129451.
    • Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience.
    • Satapathy S, Das CK, Aggarwal P, Sood A, Parihar AS, Singh SK, Mittal BR.
    • Prostate. 2022 Oct 19. doi: 10.1002/pros.24450. Epub ahead of print.
    • Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
    • Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP.
    • J Clin Oncol. 2022 Oct 18:JCO2102947. doi: 10.1200/JCO.21.02947. Epub ahead of print.

    Related:

    •• Identifier: NCT02893917: Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer. (ClinicalTrials.gov . Accessed 2022 Oct 19.)

    •• Research news: Cediranib Plus Olaparib Elicits rPFS Benefit in Metastatic Castration-Resistant Prostate Cancer. (OncLive)

    • Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
    • Loehr A, Hussain A, Patnaik A, Bryce AH, Castellano D, Font A, Shapiro J, Zhang J, Sautois B, Vogelzang NJ, Chatta G, Courtney K, Harzstark A, Ricci F, Despain D, Watkins S, King C, Nguyen M, Simmons AD, Chowdhury S, Abida W.
    • Eur Urol. 2022 Oct 12:S0302-2838(22)02639-2. doi: 10.1016/j.eururo.2022.09.010. Epub ahead of print.

    Related:

    •• Commentary:

    BRCA Reversion Mutations in Metastatic Castration-Resistant Prostate Cancer.

    •• Letter:

    Re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.

    •• Reply:

    Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.

    • Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.
    • Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, Mishra M, Rana Z, Molitoris J, Lambert B, Delrue L, Wang H, Lowe K, Verbeke S, Van Dorpe J, Bultijnck R, Villeirs G, De Man K, Ameye F, Song DY, DeWeese T, Paller CJ, Feng FY, Wyatt A, Pienta KJ, Diehn M, Bentzen SM, Joniau S, Vanhaverbeke F, De Meerleer G, Antonarakis ES, Lotan TL, Berlin A, Siva S, Ost P, Tran PT.
    • J Clin Oncol. 2022 Oct 10;40(29):3377-3382. doi: 10.1200/JCO.22.00644. Epub 2022 Aug 24.

    Related:

    Identifier: NCT01558427: Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer. (ClinicalTrials.gov . Accessed 2022 Oct 9.)

    Identifier: NCT02680587: Stereotactic Body Radiation for Prostate Oligometastases (ORIOLE). (ClinicalTrials.gov . Accessed 2022 Oct 9.)

    • Rucaparib Meets rPFS End Point in BRCA/ATM-Mutated mCRPC.
    • Ryan C.
    • OncLive. 2022 Oct 3.

    Related:

    Identifier: NCT02975934: A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3). (ClinicalTrials.gov . Accessed 2022 Oct 5.)

    • Clovis Oncology to File sNDA for Rubraca in BRCA1/2-Mutant Prostate Cancer.
    • [No author given]
    • Precision Oncology News. 2022 Oct 3.
    • PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures.
    • McNevin CS, Cadoo K, Baird AM, Finn SP, McDermott R.
    • Cancers (Basel). 2022 Sep 29;14(19):4751. doi: 10.3390/cancers14194751.
    • Analysis of BRCA2 Copy Number Loss and Genomic Instability in Circulating Tumor Cells from Patients with Metastatic Castration-resistant Prostate Cancer.
    • Barnett ES, Schultz N, Stopsack KH, Lam ET, Arfe A, Lee J, Zhao JL, Schonhoft JD, Carbone EA, Keegan NM, Wibmer A, Wang Y, Solit DB, Abida W, Wenstrup R, Scher HI.
    • Eur Urol. 2022 Sep 16:S0302-2838(22)02561-1. doi: 10.1016/j.eururo.2022.08.010. Epub ahead of print.
    • Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA.
    • Swami U, Zimmerman RM, Nussenzveig RH, Hernandez EJ, Jo Y, Sayegh N, Wesolowski S, Kiedrowski LA, Barata PC, Lemmon GH, Bilen MA, Heath EI, Nandagopal L, Babiker HM, Pal SK, Lilly M, Maughan BL, Haaland B, Yandell M, Sartor O, Agarwal N.
    • Front Oncol. 2022 Sep 15;12:966534. doi: 10.3389/fonc.2022.966534.

    Related:

    •• Commentary:

    Editorial: Prostate Cancer Genomics: Application at Different Stages of a Patient's Journey.

    • Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
    • Truong H, Breen K, Nandakumar S, Sjoberg DD, Kemel Y, Mehta N, Lenis AT, Reisz PA, Carruthers J, Benfante N, Joseph V, Khurram A, Gopalan A, Fine SW, Reuter VE, Vickers AJ, Birsoy O, Liu Y, Walsh M, Latham A, Mandelker D, Stadler ZK, Pietzak E, Ehdaie B, Touijer KA, Laudone VP, Slovin SF, Autio KA, Danila DC, Rathkopf DE, Eastham JA, Chen Y, Morris MJ, Offit K, Solit DB, Scher HI, Abida W, Robson ME, Carlo MI.
    • Eur Urol. 2022 Sep 14:S0302-2838(22)02619-7. doi: 10.1016/j.eururo.2022.08.028. Epub ahead of print.
    • NICE Finds Lynparza Not Cost-Effective in BRCA1/2-Mutated Advanced Prostate Cancer.
    • [No author given]
    • Precision Oncology News. Business, Policy & Funding. 2022 Sep 7.
    • Study: PARP inhibitor treatment for metastatic prostate cancer shows most benefit in men with inherited BRCA mutations.
    • [No author given]
    • FORCE. XRAY. 2022 Sep 6.

    Related:

    Original research:

    Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.

    • Novel germline mutations for active surveillance and imaging strategies in prostate cancer.
    • Mondschein R, Taylor R, Thorne H, Bolton D.
    • Curr Opin Urol. 2022 Sep 1;32(5):456-461. doi: 10.1097/MOU.0000000000001024. Epub 2022 Jul 18.
    • Review
    • Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    • Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E Procopio G, de Menezes J, Girotto G, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Virizuela JA, Emmenegger U, Navratil J, Buchschacher GL, Poehlein C, Harrington EA, Desai C, Kang J, Saad F, for the PROpel Investigators.
    • NEJM Evid. 2022 Sep;1(9):EVIDoa2200043. doi: 10.1056/EVIDoa2200043. Epub 2022 Jun 3.

    Related:

    •• Identifier: NCT03732820: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer. (ClinicalTrials.gov . Accessed 2023 Feb 18.)

    •• Commentary: Should We “PROpel” Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer? (NEJM Evidence)

    • The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
    • Liu AJ, Kosiorek HE, Ueberroth BE, Jaeger E, Ledet E, Kendi AT, Tzou K, Quevedo F, Choo R, Moore CN, Ho TH, Singh P, Keole SR, Wong WW, Sartor O, Bryce AH.
    • Prostate. 2022 Sep;82(12):1202-1209. doi: 10.1002/pros.24375. Epub 2022 Jun 2.
    • Disparities in germline testing among racial minorities with prostate cancer.
    • Weise N, Shaya J, Javier-Desloges J, Cheng HH, Madlensky L, McKay RR.
    • Prostate Cancer Prostatic Dis. 2022 Sep;25(3):403-410. doi: 10.1038/s41391-021-00469-3. Epub 2021 Nov 13.
    • Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies.
    • Xu J, Resurreccion WK, Shi Z, Wei J, Wang CH, Zheng SL, Hulick PJ, Ross AE, Pavlovich CP, Helfand BT, Isaacs WB.
    • Prostate Cancer Prostatic Dis. 2022 Sep;25(3):422-430. doi: 10.1038/s41391-021-00458-6. Epub 2022 Mar 28.
    • Review
    • Olaparib outcomes in metastatic castration-resistant prostate cancer: First real-world experience in safety and efficacy from the Chinese mainland.
    • Pan J, Ye D, Zhu Y.
    • Prostate Int. 2022 Sep;10(3):142-147. doi: 10.1016/j.prnil.2022.04.005. Epub 2022 May 6.
    • Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound.
    • Chi KN, Barnicle A, Sibilla C, Lai Z, Corcoran C, Barrett JC, Adelman CA, Qiu P, Easter A, Dearden S, Oxnard GR, Agarwal N, Azad A, de Bono J, Mateo J, Olmos D, Thiery-Vuillemin A, Harrington EA.
    • Clin Cancer Res. 2022 Aug 31:OF1-OF11. doi: 10.1158/1078-0432.CCR-22-0931. Epub ahead of print.
    • Successful case of olaparib treatment for castration-resistant prostate cancer with multiple DNA repair gene mutations: Use of comprehensive genome profiling for treatment-refractory cases.
    • Hirayama Y, Kato M, Kimura K, Otoshi T, Yamasaki T, Uchida J.
    • Urol Case Rep. 2022 Aug 30;45:102210. doi: 10.1016/j.eucr.2022.102210.
    • Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data.
    • Blas L, Shiota M, Eto M.
    • Cancers (Basel). 2022 Aug 27;14(17):4161. doi: 10.3390/cancers14174161.
    • Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer.
    • Kimura H, Mizuno K, Shiota M, Narita S, Terada N, Fujimoto N, Ogura K, Hatano S, Iwasaki Y, Hakozaki N, Ishitoya S, Sumiyoshi T, Goto T, Kobayashi T, Nakagawa H, Kamoto T, Eto M, Habuchi T, Ogawa O, Momozawa Y, Akamatsu S.
    • Br J Cancer. 2022 Aug 19. doi: 10.1038/s41416-022-01915-2. Epub ahead of print.
    • Lynparza in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer.
    • Kemp A.
    • AstraZeneca. Media. Press Releases. 2022 Aug 16.
    • Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance.
    • Cahuzac M, Péant B, Mes-Masson AM, Saad F.
    • Cancers (Basel). 2022 Aug 11;14(16):3877. doi: 10.3390/cancers14163877.
    • BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside.
    • Boussios S, Rassy E, Moschetta M, Ghose A, Adeleke S, Sanchez E, Sheriff M, Chargari C, Pavlidis N.
    • Cancers (Basel). 2022 Aug 11;14(16):3888. doi: 10.3390/cancers14163888.
    • DNA damage repair genes alterations in genito-urinary malignancies.
    • Dariane C, Timsit MO.
    • Eur Surg Res. 2022 Aug 9. doi: 10.1159/000526415. Epub ahead of print.
    • Review
    • Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician's Perspective.
    • Matsumoto T, Shiota M, Blas L, Eto M.
    • Cancer Manag Res. 2022 Aug 8;14:2389-2397. doi: 10.2147/CMAR.S326114.
    • Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.
    • Unlu S, Kim JW.
    • Curr Oncol Rep. 2022 Aug 6. doi: 10.1007/s11912-022-01305-0. Epub ahead of print.
    • Review
    • What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib.
    • Petrylak DP, Watkins SP, Loehr A.
    • Front Oncol. 2022 Aug 1;12:951348. doi: 10.3389/fonc.2022.951348.
    • When to use somatic tumor testing in prostate cancer.
    • Friedlander TW.
    • Clin Adv Hematol Oncol. 2022 Aug;20(8):487-489.
    • Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
    • Fizazi K, Retz M, Petrylak DP, Goh JC, Perez-Gracia J, Lacombe L, Zschäbitz S, Burotto M, Mahammedi H, Gravis G, Bastos DA, McCune SL, Vázquez Limón JC, Kwan EM, Castellano D, Fléchon A, Saad F, Grimm MO, Shaffer DR, Armstrong AJ, Bhagavatheeswaran P, Amin NP, Ünsal-Kaçmaz K, Wang X, Li J, Loehr A, Pachynski RK.
    • J Immunother Cancer. 2022 Aug;10(8):e004761. doi: 10.1136/jitc-2022-004761.

    Related:

    Identifier: NCT03338790: An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CheckMate 9KD). (ClinicalTrials.gov)

    • Germline genetics of prostate cancer.
    • Khan HM, Cheng HH.
    • Prostate. 2022 Aug;82 Suppl 1:S3-S12. doi: 10.1002/pros.24340.
    • Clinical implications of homologous recombination repair mutations in prostate cancer.
    • Cresta Morgado P, Mateo J.
    • Prostate. 2022 Aug;82 Suppl 1:S45-S59. doi: 10.1002/pros.24352.
    • Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.
    • Ruigrok EAM, Verkaik NS, de Blois E, de Ridder C, Stuurman D, Roobol SJ, Van Gent DC, de Jong M, Van Weerden WM, Nonnekens J.
    • Int J Mol Sci. 2022 Jul 21;23(14):8037. doi: 10.3390/ijms23148037.
    • A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer.
    • Shao C, Chang MS, Lam FC, Marley AR, Tang H, Song Y, Miller C, Brown M, Wan I, Han J, Adeboyeje G.
    • J Oncol. 2022 Jul 20;2022:5830475. doi: 10.1155/2022/5830475.
    • Emerging Biomarker-Guided Therapies in Prostate Cancer.
    • Deluce JE, Cardenas L, Lalani AK, Maleki Vareki S, Fernandes R.
    • Curr Oncol. 2022 Jul 18;29(7):5054-5076. doi: 10.3390/curroncol29070400.
    • Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
    • Chiu PKF, Lee EKC, Chan MTY, Chan WHC, Cheung MH, Lam MHC, Ma ESK, Poon DMC.
    • Front Oncol. 2022 Jul 18;12:962958. doi: 10.3389/fonc.2022.962958.

    Related:

    •• Commentary:

    Editorial: Prostate Cancer Genomics: Application at Different Stages of a Patient's Journey.

    • Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Jul 13.
    • Research news

    Related:

    Original research:

    PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.

    • Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review.
    • Chan VKY, Yang R, Wong ICK, Li X.
    • Front Pharmacol. 2022 Jul 11;13:891149. doi: 10.3389/fphar.2022.891149.
    • AZD5305 More Tolerable than Earlier PARP Agents.
    • [No author given]
    • Cancer Discov. 2022 Jul 6;12(7):1602. doi: 10.1158/2159-8290.CD-NB2022-0039.
    • News
    • Genetic testing in prostate cancer management: Considerations informing primary care.
    • Giri VN, Morgan TM, Morris DS, Berchuck JE, Hyatt C, Taplin ME.
    • CA Cancer J Clin. 2022 Jul;72(4):360-371. doi: 10.3322/caac.21720. Epub 2022 Feb 24.
    • Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.
    • Roubaud G, Özgüroglu M, Penel N, Matsubara N, Mehra N, Kolinsky MP, Procopio G, Feyerabend S, Joung JY, Gravis G, Nishimura K, Gedye C, Padua C, Shore N, Thiery-Vuillemin A, Saad F, van Alphen R, Carducci MA, Desai C, Brickel N, Poehlein C, Del Rosario P, Fizazi K.
    • Eur J Cancer. 2022 Jul;170:73-84. doi: 10.1016/j.ejca.2022.04.016. Epub 2022 May 19.

    Related:

    Identifier: NCT02987543: Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study). (ClinicalTrials.gov)

    • The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management.
    • Rao A, Antonarakis ES.
    • Expert Rev Anticancer Ther. 2022 Jul;22(7):671-679. doi: 10.1080/14737140.2022.2081154. Epub 2022 May 26.
    • Review
    • BRCA2 Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series.
    • Symonds L, Konnick E, Vakar-Lopez F, Cheng HH, Schweizer MT, Nelson PS, Pritchard CC, Montgomery B.
    • JCO Precis Oncol. 2022 Jul;6:e2200091. doi: 10.1200/PO.22.00091.
    • Case report
    • Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.
    • Zurita AJ, Graf RP, Villacampa G, Raskina K, Sokol E, Jin D, Antonarakis ES, Li G, Huang RSP, Casanova-Salas I, Vivancos A, Carles J, Ross JS, Schrock AB, Oxnard GR, Mateo J.
    • JCO Precis Oncol. 2022 Jul;6:e2200195. doi: 10.1200/PO.22.00195.
    • The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer.
    • Lee AM, Saidian A, Shaya J, Nonato T, Cabal A, Randall JM, Millard F, Stewart T, Rose B, Tamayo P, McKay RR.
    • Clin Genitourin Cancer. 2022 Jun 30:S1558-7673(22)00141-0. doi: 10.1016/j.clgc.2022.06.016. Epub ahead of print.
    • PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer.
    • Dillon KM, Bekele RT, Sztupinszki Z, Hanlon T, Rafiei S, Szallasi Z, Choudhury AD, Mouw KW.
    • NPJ Precis Oncol. 2022 Jun 29;6(1):49. doi: 10.1038/s41698-022-00291-7.
    • Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer.
    • McClurg DP, Urquhart G, McGoldrick T, Chatterji S, Miedzybrodzka Z, Speirs V, Elsberger B.
    • Cancers (Basel). 2022 Jun 28;14(13):3175. doi: 10.3390/cancers14133175.
    • Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.
    • Saad F, de Bono J, Barthélémy P, Dorff T, Mehra N, Scagliotti G, Stirling A, Machiels JP, Renard V, Maruzzo M, Higano CS, Gurney H, Healy C, Bhattacharyya H, Arondekar B, Niyazov A, Fizazi K.
    • Eur Urol. 2022 Jun 21:S0302-2838(22)02407-1. doi: 10.1016/j.eururo.2022.05.030. Epub ahead of print.
    • A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report.
    • Iwasawa T, Kosaka T, Morita S, Mikami S, Nakamura K, Hongo H, Nishihara H, Oya M.
    • BMC Med Genomics. 2022 Jun 20;15(1):138. doi: 10.1186/s12920-022-01286-w.
    • PARP Inhibitors: A New Horizon for Patients with Prostate Cancer.
    • Congregado B, Rivero I, Osmán I, Sáez C, Medina López R.
    • Biomedicines. 2022 Jun 15;10(6):1416. doi: 10.3390/biomedicines10061416.
    • The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair.
    • Pacheco-Barcia V, Muñoz A, Castro E, Ballesteros AI, Marquina G, González-Díaz I, Colomer R, Romero-Laorden N.
    • Cancers (Basel). 2022 Jun 15;14(12):2950. doi: 10.3390/cancers14122950.
    • Pilot Study: PARP1 Imaging in Advanced Prostate Cancer.
    • Dehdashti F, Reimers MA, Shoghi KI, Chen DL, Luo J, Rogers B, Pachynski RK, Sreekumar S, Weimholt C, Zhou D.
    • Mol Imaging Biol. 2022 Jun 14. doi: 10.1007/s11307-022-01746-w. Epub ahead of print.
    • Germline Mutations in Patients With Early-Onset Prostate Cancer.
    • Tang T, Tan X, Wang Z, Wang S, Wang Y, Xu J, Wei X, Zhang D, Liu Q, Jiang J.
    • Front Oncol. 2022 Jun 6;12:826778. doi: 10.3389/fonc.2022.826778.
    • Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study.
    • Colosini A, Bernardi S, Foroni C, Pasinetti N, Guerini AE, Russo D, Bresciani R, Tomasi C, Magrini SM, Bardoscia L, Triggiani L.
    • Biomedicines. 2022 Jun 4;10(6):1321. doi: 10.3390/biomedicines10061321.
    • Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies.
    • Russo A, Incorvaia L, Capoluongo E, Tagliaferri P, Gori S, Cortesi L, Genuardi M, Turchetti D, De Giorgi U, Di Maio M, Barberis M, Dessena M, Del Re M, Lapini A, Luchini C, Jereczek-Fossa BA, Sapino A, Cinieri S; Italian Scientific Societies.
    • ESMO Open. 2022 Jun;7(3):100459. doi: 10.1016/j.esmoop.2022.100459. Epub 2022 May 19.
    • PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.
    • Sokol ES, Jin DX, Fine A, Trabucco SE, Maund S, Frampton G, Molinero L, Antonarakis ES.
    • JCO Precis Oncol. 2022 Jun;6:e2100531. doi: 10.1200/PO.21.00531.

    Related:

    Research news: Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients. (Precision Oncology News)

    • Clinical Significance of Gene Mutations and Polymorphic Variants and their Association with Prostate Cancer Risk in Polish Men.
    • Heise M, Jarzemski P, Nowak D, Bak A, Junkiert-Czarnecka A, Pilarska-Deltow M, Borysiak M, Pilarska B, Haus O.
    • Cancer Control. 2022 Jan-Dec [2022 May 31];29:10732748211062342. doi: 10.1177/10732748211062342.
    • Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
    • Leibowitz BD, Dougherty BV, Bell JSK, Kapilivsky J, Michuda J, Sedgewick AJ, Munson WA, Chandra TA, Dry JR, Beaubier N, Igartua C, Taxter T.
    • BMC Cancer. 2022 May 28;22(1):587. doi: 10.1186/s12885-022-09669-z.
    • Metastatic Castration-Resistant Prostate Cancer with BRCA2 Mutation: The Challenge Incorporating PARP Inhibitors and Platinum in Treatment Sequencing.
    • Nogueira Costa I, Reis J, Meireles S, Ribeiro MJ, Barbosa M, Augusto I.
    • Eur J Case Rep Intern Med. 2022 May 24;9(5):003331. doi: 10.12890/2022_003331.
    • Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis.
    • Dong B, Yang B, Chen W, Du X, Fan L, Yao X, Xue W.
    • Med Oncol. 2022 May 23;39(5):96. doi: 10.1007/s12032-022-01648-5.
    • Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis.
    • Matsubara N, Nishimura K, Kawakami S, Joung JY, Uemura H, Goto T, Kwon TG, Sugimoto M, Kato M, Wang SS, Pang ST, Chen CH, Fujita T, Nii M, Shen L, Dujka M, Hussain M, de Bono J.
    • Jpn J Clin Oncol. 2022 May 5;52(5):441-448. doi: 10.1093/jjco/hyac015.
    • The role of genetic testing in prostate cancer screening, diagnosis, and treatment.
    • de la Calle CM, Bhanji Y, Pavlovich CP, Isaacs WB.
    • Curr Opin Oncol. 2022 May 1;34(3):212-218. doi: 10.1097/CCO.0000000000000823.
    • Review
    • Implications of DNA damage repair alterations for the management of prostate cancer.
    • Lozano R, Olmos D, Castro E.
    • Curr Opin Urol. 2022 May 1;32(3):302-310. doi: 10.1097/MOU.0000000000000983. Epub 2022 Mar 9.
    • Review
    • Advances in urologic oncology "OncoUrology Forum Special Edition": The best of 2020.
    • Gómez-Veiga F, Alcaraz-Asensio A, Burgos-Revilla JM, Cózar-Olmo FJ.
    • Actas Urol Esp (Engl Ed). 2022 May;46(4):214-222. English, Spanish. doi: 10.1016/j.acuroe.2021.09.001. Epub 2021 Nov 26.
    • Review, Conference report
    • PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer.
    • Flippot R, Patrikidou A, Aldea M, Colomba E, Lavaud P, Albigès L, Naoun N, Blanchard P, Terlizzi M, Garcia C, Bernard-Tessier A, Fuerea A, Di Palma M, Escudier B, Loriot Y, Baciarello G, Fizazi K.
    • Drugs. 2022 May;82(7):719-733. doi: 10.1007/s40265-022-01703-5. Epub 2022 May 5.
    • Review
    • Volunteer Spotlight – Mike Philbin.
    • [No author given]
    • FORCE. Blog. 2022 Apr 29.
    • Janssen Seeking European Union Approval for Zejula in HRR-Positive Prostate Cancer.
    • [No author given]
    • Precision Oncology News. Biomarkers. BRCA. 2022 Apr 28.
    • Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors.
    • Price MJ, Vashistha V, Winski D, Kelley MJ, Bitting RL, Montgomery B.
    • JCO Precis Oncol. 2022 Apr [Published online: 2022 Apr 27];6:e2100461. doi: 10.1200/PO.21.00461.
    • Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance.
    • Brady L, Newcomb LF, Zhu K, Zheng Y, Boyer H, Sarkar N, McKenney JK, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss MA, Martin F, Morgan TM, Thompson IM, Wagner AA, Pritchard CC, Lin DW, Nelson PS.
    • Cancer Med. 2022 Apr 25. doi: 10.1002/cam4.4778. Epub ahead of print.
    • Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report.
    • Yuan F, Liu N, Yang MZ, Zhang XT, Luo H, Zhou H.
    • World J Clin Cases. 2022 Apr 16;10(11):3461-3471. doi: 10.12998/wjcc.v10.i11.3461.
    • Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer According to Somatic Damage DNA Repair Gene Alterations.
    • Neviere Z, Coquan E, Brachet PE, Meriaux E, Bonnet I, Krieger S, Castéra L, Vaur D, Boulouard F, Leconte A, Lequesne J, Lelaidier A, Ricou A, Joly F.
    • Curr Oncol. 2022 Apr 15;29(4):2776-2791. doi: 10.3390/curroncol29040226.
    • Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).
    • Hussain M, Corcoran C, Sibilla C, Fizazi K, Saad F, Shore N, Sandhu S, Mateo J, Olmos D, Mehra N, Kolinsky MP, Roubaud G, Özgüroglu M, Matsubara N, Gedye C, Choi YD, Padua C, Kohlmann A, Huisden R, Elvin JA, Kang J, Adelman CA, Allen A, Poehlein C, de Bono J.
    • Clin Cancer Res. 2022 Apr 14;28(8):1518-1530. doi: 10.1158/1078-0432.CCR-21-3940.
    • Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Apr 12.

    Related:

    Identifier: NCT04644068: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA). (ClinicalTrials.gov)

    • Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
    • Slootbeek PHJ, Kloots ISH, Smits M, van Oort IM, Gerritsen WR, Schalken JA, Ligtenberg MJL, Grünberg K, Kroeze LI, Bloemendal HJ, Mehra N.
    • Br J Cancer. 2022 Apr;126(6):907-916. doi: 10.1038/s41416-021-01663-9. Epub 2021 Dec 15.
    • Highlights in advanced prostate cancer from the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium: commentary.
    • Armstrong AJ.
    • Clin Adv Hematol Oncol. 2022 Apr;20 Suppl 8(4):16-22.

    Related:

    Review:

    Phase 3 MAGNITUDE Study: First Results of Niraparib With Abiraterone Acetate and Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With and Without Homologous Recombination Repair Gene Alterations.

    Review:

    PROpel: Phase III Trial of Olaparib and Abiraterone vs Placebo and Abiraterone as First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer.

    Commentary:

    Highlights in Advanced Prostate Cancer From the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium: Commentary.

    • MRI appearance of BRCA-associated prostate cancer.
    • Kamal O, Foster BR, Young DJ, Hansel DE, Coakley FV.
    • Clin Imaging. 2022 Apr;84:135-139. doi: 10.1016/j.clinimag.2022.02.007. Epub 2022 Feb 19.
    • Clinical Utility of Liquid Biopsy to Identify Genomic Heterogeneity and Secondary Cancer Diagnoses: A Case Report.
    • Hemenway G, Tierno MB, Nejati R, Sosa R, Zibelman M.
    • Case Rep Oncol. 2022 Feb 7 [eCollection Jan-Apr 2022];15(1):78-85. doi: 10.1159/000521841.
    • Pre-activation of autophagy impacts response to olaparib in prostate cancer cells.
    • Cahuzac M, Langlois P, Péant B, Fleury H, Mes-Masson AM, Saad F.
    • Commun Biol. 2022 Mar 22;5(1):251. doi: 10.1038/s42003-022-03210-5.
    • PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers.
    • Teyssonneau D, Thiery-Vuillemin A, Dariane C, Barret E, Beauval JB, Brureau L, Créhange G, Fiard G, Fromont G, Gauthé M, Ruffion A, Renard-Penna R, Mathieu R, Sargos P, Rouprêt M, Ploussard G, Roubaud G, On Behalf Of The Cc-Afu Cancerology Committee Of The Association Française d'Urologie.
    • J Clin Med. 2022 Mar 21;11(6):1734. doi: 10.3390/jcm11061734.
    • Biomarkers for characterization and therapeutic orientation in castration-resistant prostate cancer.
    • Plata Bello A, Tamayo Jover MA, Gutierrez Nicolas F, Acosta López S, Concepción Masip T, Plata Bello J.
    • Arch Esp Urol. 2022 Mar;75(2):195-202. English, Spanish.
    • Review
    • PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.
    • Bienkowski M, Tomasik B, Braun M, Jassem J.
    • Cancer Treat Rev. 2022 Mar;104:102359. doi: 10.1016/j.ctrv.2022.102359.Epub 2022 Feb 11.
    • Review
    • Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan.
    • Leith A, Ribbands A, Kim J, Last M, Barlow S, Yang L, Ghate SR.
    • Future Oncol. 2022 Mar;18(8):937-951. doi: 10.2217/fon-2021-1113. Epub 2022 Jan 19.
    • Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
    • Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K; GALAHAD investigators.
    • Lancet Oncol. 2022 Mar;23(3):362-373. doi: 10.1016/S1470-2045(21)00757-9. Epub 2022 Feb 4.

    Related:

    Identifier: NCT02854436: An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies (Galahad). (ClinicalTrials.gov)

    Research news: Study: PARP inhibitor treatment for metastatic prostate cancer shows most benefit in men with inherited BRCA mutations. (FORCE. XRAY)

    • Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
    • Thiery-Vuillemin A, de Bono J, Hussain M, Roubaud G, Procopio G, Shore N, Fizazi K, Dos Anjos G, Gravis G, Joung JY, Matsubara N, Castellano D, Degboe A, Gresty C, Kang J, Allen A, Poehlein C, Saad F.
    • Lancet Oncol. 2022 Mar;23(3):393-405. doi: 10.1016/S1470-2045(22)00017-1. Epub 2022 Feb 11.
    • Recherche d’altérations des gènes de réparation de l’ADN dans le cancer de la prostate : mise au point pratique du Comité de cancérologie de l’association française d’urologie [DNA repair gene alterations testing in prostate cancer : A practical update by the prostate cancer committee of the french association of urology].
    • Ploussard G, Beauval JB, Mathieu R, Barret E, Brureau L, Créhange G, Dariane C, Fiard G, Gauthé M, Renard-Penna R, Ruffion A, Sargos P, Rouprêt M, Roubaud G, Fromont G.
    • Prog Urol. 2022 Mar;32(3):155-164. French. doi: 10.1016/j.purol.2021.12.007. Epub 2022 Feb 4.
    • Guideline. [Article in French]
    • DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy.
    • Zhu S, Zhang Z, Zhang H, Liu Z, Liu M, Liu Q, Zang L, Wang L, Ji J, Wu B, Sun L, Zhang Z, Cao H, Wang Y, Wang H, Shang Z, Niu Y.
    • Prostate. 2022 Mar;82(4):464-474. doi: 10.1002/pros.24292. Epub 2022 Jan 17.
    • PARP Inhibitors: Improving Outcomes in Metastatic Prostate Cancer.
    • Nelson R.
    • Medscape. 2022 Feb 22.
    • RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer.
    • Miao C, Tsujino T, Takai T, Gui F, Tsutsumi T, Sztupinszki Z, Wang Z, Azuma H, Szallasi Z, Mouw KW, Zou L, Kibel AS, Jia L.
    • Sci Adv. 2022 Feb 18;8(7):eabl9794. doi: 10.1126/sciadv.abl9794. Epub 2022 Feb 18.
    • Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.
    • Labadie BW, Morris DS, Bryce AH, Given R, Zhang J, Abida W, Chowdhury S, Patnaik A.
    • Cancer Manag Res. 2022 Feb 17;14:673-686. doi: 10.2147/CMAR.S335962.
    • PARP Inhibitors Show Frontline Prostate Cancer Benefit; Conflicting Biomarker Data Raise Questions.
    • Hopkins C.
    • Precision Oncology News. Disease Areas. Cancer. 2022 Feb 17.
    • Conference report
    • Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers.
    • Clark R, Herrera-Caceres J, Kenk M, Fleshner N.
    • Cancers (Basel). 2022 Feb 16;14(4):1004. doi: 10.3390/cancers14041004.
    • PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's New, and What's Coming?
    • Marchetti A, Rosellini M, Nuvola G, Tassinari E, Mollica V, Rizzo A, Santoni M, Cimadamore A, Farolfi A, Montironi R, Fanti S, Massari F.
    • Cancers (Basel). 2022 Feb 11;14(4):907. doi: 10.3390/cancers14040907.
    • BRCA2, Early-Stage Prostate Cancer and a Decision at 54.
    • Axler J.
    • FORCE. Blog. 2022 Feb 11.
    • Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now?
    • Rao A, Moka N, Hamstra DA, Ryan CJ.
    • Cancers (Basel). 2022 Feb 4;14(3):801. doi: 10.3390/cancers14030801.
    • Poly-ADP-Ribose-Polymerase(PARP)-Inhibitoren als genetisch basierte Präzisionstherapie beim metastasierten kastrationsresistenten Prostatakarzinom (mCRPC) [Poly(ADP-ribose) polymerase (PARP-)inhibitors as genetically based precision therapy in metastatic castration-resistent prostate cancer (mCRPC)].
    • Heidegger I, Becker C, Tsaur I, Todenhöfer T; Fachgruppe Molekulare Urologie der Arbeitsgruppe urologische Forschung (AuF) der Deutschen Gesellschaft für Urologie.
    • Urologe A. 2022 Feb;61(2):187-192. German. doi: 10.1007/s00120-021-01754-8. Epub 2022 Jan 10.
    • Review. [Article in German]
    • FDA Grants Fast Track Status to CX-5461 for Breast and Ovarian Cancers With BRCA1/2, PALB2, or Other HRD Mutations.
    • Rosa K.
    • OncLive. 2022 Jan 25.

    Related:

    News release: Senhwa’s Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations. (Senhwa Biosciences. Accessed 2022 Oct 5.)

    Identifier: NCT04890613: Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation. (ClinicalTrials.gov . Accessed 2022 Oct 5.)

    • What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes.
    • Palicelli A, Croci S, Bisagni A, Zanetti E, De Biase D, Melli B, Sanguedolce F, Ragazzi M, Zanelli M, Chaux A, Cañete-Portillo S, Bonasoni MP, Ascani S, De Leo A, Giordano G, Landriscina M, Carrieri G, Cormio L, Gandhi J, Nicoli D, Farnetti E, Piana S, Tafuni A, Bonacini M.
    • Biomedicines. 2022 Jan 22;10(2):236. doi: 10.3390/biomedicines10020236.
    • Platinum-Based Neoadjuvant Chemotherapy Before Radical Prostatectomy for Locally Advanced Prostate Cancer With Homologous Recombination Deficiency: A Case Report.
    • Zhuang J, Zhang S, Qiu X, Fu Y, Ai S, Zhao T, Yang Y, Guo H.
    • Front Oncol. 2022 Jan 5;11:777318. doi: 10.3389/fonc.2021.777318.
    • Défauts de la recombinaison homologue et inhibiteurs de PARP en thérapeutique [Homologous recombination deficiency and PARP inhibitors in therapeutics].
    • Salaün H, Saint-Ghislain M, Bellesoeur A, Beuzeboc P, Neuzillet C, Diéras V, Stern MH, Rodrigues M.
    • Bull Cancer. 2022 Jan;109(1):76-82. French. doi: 10.1016/j.bulcan.2021.09.015. Epub 2021 Nov 17.
    • Review, [Article in French]
    • Genetic predisposition to prostate cancer: an update.
    • Ni Raghallaigh H, Eeles R.
    • Fam Cancer. 2022 Jan;21(1):101-114. doi: 10.1007/s10689-021-00227-3. Epub 2021 Jan 24.
    • PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls.
    • Franza A, Claps M, Procopio G.
    • Transl Oncol. 2022 Jan;15(1):101263. doi: 10.1016/j.tranon.2021.101263. Epub 2021 Nov 8.
    • Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.
    • Hofstad M, Huang EY, Woods A, Yin Y, Desai NB, Raj GV.
    • Crit Rev Oncog. 2022;27(1):81-96. doi: 10.1615/CritRevOncog.2022043233.
    • Review
    • Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
    • Wu K, Liang J, Shao Y, Xiong S, Feng S, Li X.
    • Front Pharmacol. 2021 Dec 17;12:777663. doi: 10.3389/fphar.2021.777663.
    • Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer.
    • De Sarkar N, Dasgupta S, Chatterjee P, Coleman I, Ha G, Ang LS, Kohlbrenner EA, Frank SB, Nunez TA, Salipante SJ, Corey E, Morrissey C, Van Allen E, Schweizer MT, Haffner MC, Patel R, Hanratty B, Lucas JM, Dumpit RF, Pritchard CC, Montgomery RB, Nelson PS.
    • JCI Insight. 2021 Dec 8;6(23):e152789. doi: 10.1172/jci.insight.152789.
    • Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate.
    • Kang M, Lee H, Byeon SJ, Kwon GY, Jeon SS.
    • Int J Mol Sci. 2021 Dec 4;22(23):13125. doi: 10.3390/ijms222313125.
    • Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk.
    • Bancroft EK, Raghallaigh HN, Page EC, Eeles RA.
    • Curr Genet Med Rep. 2021 [Dec];9(4):47-58. doi: 10.1007/s40142-021-00202-5. Epub 2021 Oct 8.
    • Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.
    • Aldea M, Lam L, Orillard E, Llacer Perez C, Saint-Ghislain M, Gravis G, Fléchon A, Roubaud G, Barthelemy P, Ricci F, Priou F, Neviere Z, Beaufils M, Laguerre B, Hardy AC, Helissey C, Ratta R, Borchiellini D, Pobel C, Joly F, Castro E, Thiery-Vuillemin A, Baciarello G, Fizazi K.
    • Eur J Cancer. 2021 Dec;159:87-97. doi: 10.1016/j.ejca.2021.09.029. Epub 2021 Nov 2.
    • Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology.
    • Ziadeh T, Kourie HR.
    • Pharmacogenomics. 2021 Dec;22(18):1237-1250. doi: 10.2217/pgs-2021-0119. Epub 2021 Nov 3.
    • Review
    • Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
    • Sokolova AO, Marshall CH, Lozano R, Gulati R, Ledet EM, De Sarkar N, Grivas P, Higano CS, Montgomery B, Nelson PS, Olmos D, Sokolov V, Schweizer MT, Yezefski TA, Yu EY, Paller CJ, Sartor O, Castro E, Antonarakis ES, Cheng HH.
    • Prostate. 2021 Dec;81(16):1382-1389. doi: 10.1002/pros.24236. Epub 2021 Sep 13.
    • BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.
    • Shah S, Rachmat R, Enyioma S, Ghose A, Revythis A, Boussios S.
    • Int J Mol Sci. 2021 Nov 23;22(23):12628. doi: 10.3390/ijms222312628.
    • Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer.
    • Carr TH, Adelman C, Barnicle A, Kozarewa I, Luke S, Lai Z, Hollis S, Dougherty B, Harrington EA, Kang J, Saad F, Sala N, Thiery-Vuillemin A, Clarke NW, Hodgson D, Barrett JC.
    • Cancers (Basel). 2021 Nov 20;13(22):5830. doi: 10.3390/cancers13225830.
    • Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context.
    • Kolinsky MP, Niederhoffer KY, Kwan EM, Hotte SJ, Hamilou Z, Yip SM, Chi KN, Wyatt AW, Saad F.
    • Can Urol Assoc J. 2021 Nov 18. doi: 10.5489/cuaj.7621. Epub ahead of print.
    • Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients.
    • Lieb V, Abdulrahman A, Weigelt K, Hauch S, Gombert M, Guzman J, Bellut L, Goebell PJ, Stöhr R, Hartmann A, Wullich B, Taubert H, Wach S.
    • Cells. 2021 Nov 18;10(11):3223. doi: 10.3390/cells10113223.
    • Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer.
    • McNevin CS, Cadoo K, Baird AM, Murchan P, Sheils O, McDermott R, Finn S.
    • Cancers (Basel). 2021 Nov 14;13(22):5697. doi: 10.3390/cancers13225697.
    • Genomic Features of Radiation-Associated Muscle-Invasive Bladder Cancer.
    • Muralidhar V, Carvalho F, Preston M, Curran C, Freeman D, Sonpavde G, Kibel A, Van Allen EM, Mossanen M, Mouw KW.
    • Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):S13-S14. doi: 10.1016/j.ijrobp.2021.07.062.
    • PARP Inhibition in Advanced Prostate Cancer.
    • Fenton SE, Chalmers ZR, Hussain M.
    • Cancer J. 2021 Nov-Dec 01;27(6):457-464. doi: 10.1097/PPO.0000000000000560.
    • Review
    • Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.
    • Konecny GE, Chander C, Zhang L.
    • Cancer J. 2021 Nov-Dec 01;27(6):482-490. doi: 10.1097/PPO.0000000000000564.
    • Review
    • Vers une recherche systématique de mutations germinales pour tous les patients atteints d’un cancer de la prostate métastatique et localisé à haut risque ? [Germline testing for patients with metastatic and localized high-risk prostate cancer: Towards a widespread use?].
    • Marchand-Créty C.
    • Bull Cancer. 2021 Nov;108(11):994-998. French. doi: 10.1016/j.bulcan.2021.08.009. Epub 2021 Oct 14.
    • Commentary. [Article in French]
    • Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
    • Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, Rescigno P, Paschalis A, Bertan C, Baker C, Goodall J, Miranda S, Riisnaes R, Figueiredo I, Ferreira A, Pereira R, Crespo M, Gurel B, Nava Rodrigues D, Pettitt SJ, Yuan W, Serra V, Rekowski J, Lord CJ, Hall E, Mateo J, de Bono JS.
    • Cancer Discov. 2021 Nov;11(11):2812-2827. doi: 10.1158/2159-8290.CD-21-0007. Epub 2021 May 27.
    • PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations.
    • von Werdt A, Brandt L, Schärer OD, Rubin MA.
    • JCO Precis Oncol. 2021 Oct 22;5:PO.21.00152. doi: 10.1200/PO.21.00152.
    • Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report.
    • McFarland TR, Tandar CE, Agarwal N, Swami U.
    • Cancer Treat Res Commun. 2021;29:100480. doi: 10.1016/j.ctarc.2021.100480. Epub 2021 Oct 20.
    • First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations.
    • Omura M, Kosaka T, Aimono E, Nakamura K, Hongo H, Mikami S, Nishihara H, Oya M.
    • IJU Case Rep. 2021 Oct 20;5(1):41-44. doi: 10.1002/iju5.12383.
    • Genetics of prostate cancer and its utility in treatment and screening.
    • Benafif S, Ni Raghallaigh H, McHugh J, Eeles R.
    • Adv Genet. 2021;108:147-199. doi: 10.1016/bs.adgen.2021.08.006. Epub 2021 Oct 19.
    • Review. Book chapter
    • Inherited Mutations in Chinese Men With Prostate Cancer.
    • Zhu Y, Wei Y, Zeng H, Li Y, Ng CF, Zhou F, He C, Sun G, Ni Y, Chiu PKF, Teoh JYC, Wang B, Pan J, Wan F, Dai B, Qin X, Lin G, Gan H, Wu J, Ye D.
    • J Natl Compr Canc Netw. 2021 Oct 15;20(1):54-62. doi: 10.6004/jnccn.2021.7010.
    • Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study.
    • Loehr A, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Hussain A, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg C, Watkins SP, Despain D, Simmons AD, Dowson M, Golsorkhi T, Chowdhury S, Abida W.
    • Clin Cancer Res. 2021 Oct 1:clincanres.2199.2021. doi: 10.1158/1078-0432.CCR-21-2199. Epub ahead of print.
    • Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
    • Fujimoto N, Harada K, Shiota M, Tomisaki I, Minato A, Nagata Y, Kimuro R, Harada M, Fujisawa M.
    • Anticancer Res. 2021 Oct;41(10):4687-4695. doi: 10.21873/anticanres.15282.
    • [The Clinical Utility of Liquid Biopsies as Biomarkers in Metastatic Prostate Cancer].
    • Sumiyoshi T, Akamatsu S.
    • Gan To Kagaku Ryoho. 2021 Oct;48(10):1203-1208. Japanese.
    • Review, [Article in Japanese]
    • Determinants of Homologous Recombination Deficiency in Pancreatic Cancer.
    • Wattenberg MM, Reiss KA.
    • Cancers (Basel). 2021 Sep 21;13(18):4716. doi: 10.3390/cancers13184716.
    • Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer.
    • Mizuno K, Sumiyoshi T, Okegawa T, Terada N, Ishitoya S, Miyazaki Y, Kojima T, Katayama H, Fujimoto N, Hatakeyama S, Shiota M, Yoshimura K, Matsui Y, Narita S, Matsumoto H, Kurahashi R, Kanno H, Ito K, Kimura H, Kamiyama Y, Sunada T, Goto T, Kobayashi T, Yamada H, Tsuchiya N, Kamba T, Matsuyama H, Habuchi T, Eto M, Ohyama C, Ito A, Nishiyama H, Okuno H, Kamoto T, Fujimoto A, Ogawa O, Akamatsu S.
    • Clin Cancer Res. 2021 Sep 15:clincanres.2328.2021. doi: 10.1158/1078-0432.CCR-21-2328. Epub ahead of print.
    • Genetic Aberrations of DNA Repair Pathways in Prostate Cancer: Translation to the Clinic.
    • Ghose A, Moschetta M, Pappas-Gogos G, Sheriff M, Boussios S.
    • Int J Mol Sci. 2021 Sep 10;22(18):9783. doi: 10.3390/ijms22189783.
    • Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium.
    • Iacovelli R, Astore S, Ciccarese C, Cannella MA, Bove P, Iacovelli V, Tortora G.
    • Expert Rev Anticancer Ther. 2021 Sep 9:1-4. doi: 10.1080/14737140.2021.1976148. Epub ahead of print.
    • Conference report
    • Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
    • de Bono JS, Mehra N, Scagliotti GV, Castro E, Dorff T, Stirling A, Stenzl A, Fleming MT, Higano CS, Saad F, Buttigliero C, van Oort IM, Laird AD, Mata M, Chen HC, Healy CG, Czibere A, Fizazi K.
    • Lancet Oncol. 2021 Sep;22(9):1250-1264. doi: 10.1016/S1470-2045(21)00376-4. Epub 2021 Aug 10.

    Related:

    Commentary:

    An important step towards smarter screening for prostate cancer.

    Commentary:

    Talazoparib: a new biomarker-directed therapy in advanced prostate cancer.

    • Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations.
    • Hesterberg AB, Gordetsky JB, Hurley PJ.
    • Urology. 2021 Sep;155:47-54. doi: 10.1016/j.urology.2021.05.028. Epub 2021 May 28.
    • Review
    • Novel Case of Isolated Peritoneal Carcinomatosis from Metastatic Prostate Cancer Carrying a Pathogenic BRCA Mutation Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    • King MC, Sardi A, Velez-Mejia C, Sittig M, Ledakis P.
    • Urology. 2021 Sep;155:210-213. doi: 10.1016/j.urology.2021.05.026. Epub 2021 May 25.
    • Case report
    • A novel germline BRCA2 mutation in a Chinese patient with prostate cancer sensitive to platinum chemotherapy: a case report.
    • Jiang L, Bai Z, Zhu S, Zhao T, Yang Y, Li Z, Chen D, Wu Z, Wang Y, Zhou F, Li Y.
    • BMC Urol. 2021 Aug 23;21(1):114. doi: 10.1186/s12894-021-00879-4.
    • Subclone eradication analysis identifies targets for enhanced cancer therapy and reveals L1 retrotransposition as a dynamic source of cancer heterogeneity.
    • Ketola K, Kaljunen H, Taavitsainen S, Kaarijärvi R, Järvelä E, Rodriguez Martin B, Haase K, Woodcock DJ, Tubio J, Wedge DC, Nykter M, Bova GS.
    • Cancer Res. 2021 Aug 4:canres.0371.2021. doi: 10.1158/0008-5472.CAN-21-0371. Epub ahead of print.
    • Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib.
    • [No author given]
    • GenomeWeb. Disease Areas. Cancer. 2021 Aug 3.
    • Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP.
    • Robinson AG, Izard JP, Vera-Badillo FE.
    • Eur Urol. 2021 Aug;80(2):123-126. doi: 10.1016/j.eururo.2021.03.001. Epub 2021 Mar 26.
    • Commentary
    • Germline BRCA1 Mutation and Prostate Cancer: Be Careful on Causality.
    • Boilève A, Lavaud P, Caron O.
    • Eur Urol Oncol. 2021 Aug;4(4):674-675. doi: 10.1016/j.euo.2021.06.004. Epub 2021 Jun 19.
    • Letter, Comment

    Related:

    Review:

    Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.

    • Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?
    • Li Y, Lin S, Zhong L, Luo S, Huang X, Huang X, Dong L, Xu X, Weng X.
    • Pharmacogenomics. 2021 Aug;22(13):809-819. doi: 10.2217/pgs-2021-0061. Epub 2021 Sep 14.
    • Genetic Contribution to Metastatic Prostate Cancer.
    • Sokolova AO, Obeid EI, Cheng HH.
    • Urol Clin North Am. 2021 Aug;48(3):349-363. doi: 10.1016/j.ucl.2021.03.005. Epub 2021 Jun 10.
    • Review
    • Genetically Informed Prostate Cancer Treatment for Metastatic Disease.
    • Siebert AL, Szymaniak BM, Numan Y, Morgans AK.
    • Urol Clin North Am. 2021 Aug;48(3):365-371. doi: 10.1016/j.ucl.2021.03.006. Epub 2021 Jun 10.
    • Review
    • Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.
    • Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi N, Barata P, Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES.
    • JCO Precis Oncol. 2021 Jul 22;5:PO.21.00070. doi: 10.1200/PO.21.00070.
    • Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations.
    • McFarland TR, Kessel A, Swami U, Agarwal N.
    • Am J Transl Res. 2021 Jul 15;13(7):7427-7439.
    • PARP inhibitors in advanced prostate cancer: when to use them?
    • Díaz-Mejía N, García-Illescas D, Morales-Barrera R, Suarez C, Planas J, Maldonado X, Carles J, Mateo J.
    • Endocr Relat Cancer. 2021 Jul 15;28(8):T79-T93. doi: 10.1530/ERC-21-0133.
    • Genomic Profiling of Prostate Cancer: An Updated Review.
    • Hatano K, Nonomura N.
    • World J Mens Health. 2021 Jul 14. doi: 10.5534/wjmh.210072. Epub ahead of print.
    • Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
    • Privé BM, Slootbeek PHJ, Laarhuis BI, Naga SP, van der Doelen MJ, van Kalmthout LWM, de Keizer B, Ezziddin S, Kratochwil C, Morgenstern A, Bruchertseifer F, Ligtenberg MJL, Witjes JA, van Oort IM, Gotthardt M, Heskamp S, Janssen MJR, Gerritsen WR, Nagarajah J, Mehra N.
    • Prostate Cancer Prostatic Dis. 2021 Jul 12. doi: 10.1038/s41391-021-00424-2. Epub ahead of print.
    • 25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology.
    • Dorff TB, O'Neil B, Hoffman KE, Lin DW, Loughlin KR, Dall'Era M.
    • Urol Oncol. 2021 Jul 12:S1078-1439(21)00175-7. doi: 10.1016/j.urolonc.2021.04.016. Epub ahead of print.
    • Review
    • Prostate Cancer in 2021: Novelties in Prognostic and Therapeutic Biomarker Evaluation.
    • Cimadamore A, Mazzucchelli R, Lopez-Beltran A, Massari F, Santoni M, Scarpelli M, Cheng L, Montironi R.
    • Cancers (Basel). 2021 Jul 11;13(14):3471. doi: 10.3390/cancers13143471.
    • Olaparib for the treatment of metastatic prostate cancer.
    • Dror CM, Wyatt AW, Chi KN.
    • Future Oncol. 2021 Jul;17(19):2413-2429. doi: 10.2217/fon-2020-1245. Epub 2021 Mar 26.
    • Review
    • Circulating tumor DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
    • Zhao J, Sun G, Zhu S, Dai J, Chen J, Zhang M, Ni Y, Zhang H, Shen P, Zhao X, Zhang B, Pan X, Nie L, Yin X, Liang J, Zhang X, Wang Z, Zhu X, Liao B, Liu Z, Armstrong CM, Gao AC, Huang H, Chen N, Zeng H.
    • BJU Int. 2021 Jun 29. doi: 10.1111/bju.15530. Epub ahead of print.
    • Das metastasierte kastrationsresistente Prostatakarzinom [Metastatic castration-resistant prostate cancer].
    • Henriques V, Wenzel M, Demes MC, Köllermann J.
    • Pathologe. 2021 Jun 25. German. doi: 10.1007/s00292-021-00956-3. Epub ahead of print.
    • Review. [Article in German]
    • A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.
    • Calagua C, Ficial M, Jansen CS, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku AT, Voznesensky O, Sykes DB, Saylor PJ, Ye H, Signoretti S, Kissick H, Sowalsky AG, Balk SP, Einstein DJ.
    • Clin Cancer Res. 2021 Jun 24:clincanres.0121.2021. doi: 10.1158/1078-0432.CCR-21-0121. Epub ahead of print.
    • Chinese Regulators Approve Lynparza for BRCA1/2-Mutated mCRPC.
    • [No author given]
    • Precision Oncology News. Biomarkers. BRCA. 2021 Jun 24.
    • Pfizer Studying Talzenna in Advanced Prostate Cancer Patients With DNA Damage Response Gene Defects.
    • [No author given]
    • Precision Oncology News. Cancer Specialties. Prostate Cancer. 2021 Jun 23.
    • The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre International Retreat.
    • Clark R, Kenk M, McAlpine K, Thain E, Farncombe KM, Pritchard CC, Nussbaum R, Wyatt AW, de Bono J, Vesprini D, Bombard Y, Lorentz J, Narod S, Kim R, Fleshner N.
    • Can Urol Assoc J. 2021 Jun 22. doi: 10.5489/cuaj.7383. Epub ahead of print.
    • Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells.
    • Uddin MH, Li Y, Khan HY, Muqbil I, Aboukameel A, Sexton RE, Reddy S, Landesman Y, Kashyap T, Azmi AS, Heath EI.
    • Int J Mol Sci. 2021 Jun 22;22(13):6676. doi: 10.3390/ijms22136676.
    • A karboplatin-kemoterápia hatékonysága egy áttétes, kasztrációrezisztens, BRCA2-mutáció-pozitív prosztatarákos betegben. [Efficacy of carboplatin chemotherapy in a metastatic, castration-resistant, BRCA2 mutation positive prostate cancer patient.]
    • Nagy ND, Fazekas T, Baghy K, Papp G, Csizmarik A, Szucs M, Nyirády P, Szarvas T.
    • Orv Hetil. 2021 Jun 20;162(25):1004-1008. doi: 10.1556/650.2021.32112.
    • Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
    • Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS.
    • Cancer. 2021 Jun 15;127(12):1965-1973. doi: 10.1002/cncr.33487. Epub 2021 Mar 10.
    • Germline Genetic Testing for All Patients With Cancer?
    • Nelson R.
    • Medscape Oncology. 2021 Jun 15.
    • Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.
    • Martinez Chanza N, Bernard B, Barthelemy P, Accarain A, Paesmans M, Desmyter L, T'Kint de Roodenbeke D, Gil T, Sideris S, Roumeguere T, Hamid AA, Sweeney CJ.
    • Prostate Cancer Prostatic Dis. 2021 Jun 9. doi: 10.1038/s41391-021-00397-2. Epub ahead of print.
    • Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.
    • Sumanasuriya S, Seed G, Parr H, Christova R, Pope L, Bertan C, Bianchini D, Rescigno P, Figueiredo I, Goodall J, Fowler G, Flohr P, Mehra N, Neeb A, Rekowski J, Eisenberger M, Sartor O, Oudard S, Geffriaud-Ricouard C, Ozatilgan A, Chadjaa M, Macé S, Lord C, Baxter J, Pettitt S, Lambros M, Sharp A, Mateo J, Carreira S, Yuan W, de Bono JS.
    • Eur Urol. 2021 Jun 5:S0302-2838(21)01799-1. doi: 10.1016/j.eururo.2021.05.030. Epub ahead of print.
    • Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?
    • Kwon DH, Booth CM, Prasad V.
    • Eur Urol. 2021 Jun;79(6):710-712. doi: 10.1016/j.eururo.2021.02.041. Epub 2021 Mar 12.
    • Commentary
    • Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic.
    • Cimadamore A, Cheng L, Massari F, Santoni M, Pepi L, Franzese C, Scarpelli M, Lopez-Beltran A, Galosi AB, Montironi R.
    • Int J Mol Sci. 2021 May 24;22(11):5522. doi: 10.3390/ijms22115522.
    • Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy.
    • Hongo H, Kosaka T, Hayashi H, Nakamura K, Nishihara H, Mikami S, Beltran H, Oya M.
    • Asian J Androl. 2021 May 21. doi: 10.4103/aja.aja_37_21. Epub ahead of print.
    • A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer.
    • King B, McHugh J, Snape K.
    • Appl Clin Genet. 2021 May 20;14:255-266. doi: 10.2147/TACG.S261737.
    • BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored.
    • Crocetto F, Barone B, Caputo VF, Fontana M, de Cobelli O, Ferro M.
    • Diagnostics (Basel). 2021 May 19;11(5):908. doi: 10.3390/diagnostics11050908.
    • Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report.
    • Koguchi D, Tabata KI, Tsumura H, Mori K, Koh H, Iwamura M.
    • Urol Case Rep. 2021 May 17;38:101712. doi: 10.1016/j.eucr.2021.101712.
    • Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study.
    • Dong B, Fan L, Yang B, Chen W, Li Y, Wu K, Zhang F, Dong H, Cheng H, Pan J, Zhu Y, Chi C, Dong L, Sha J, Li L, Yao X, Xue W.
    • J Natl Compr Canc Netw. 2021 May 14;19(8):905-914. doi: 10.6004/jnccn.2020.7663.
    • The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.
    • Xia M, Guo Z, Hu Z.
    • Biomolecules. 2021 May 12;11(5):722. doi: 10.3390/biom11050722.
    • Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity.
    • van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Ligtenberg M, Mehra N.
    • Cancers (Basel). 2021 May 7;13(9):2249. doi: 10.3390/cancers13092249.
    • Prominent response to platinum-based chemotherapy in a patient with BRCA2 mutant-neuroendocrine prostate cancer and MDM2 amplification.
    • Daimon T, Kosaka T, Hongo H, Aimono E, Nakamura K, Mikami S, Nishihara H, Oya M.
    • IJU Case Rep. 2021 May 5;4(4):216-219. doi: 10.1002/iju5.12287.

    Related:

    Commentary:

    Editorial Comment to Prominent response to platinum-based chemotherapy in a patient with BRCA2 mutant-neuroendocrine prostate cancer and MDM2 amplification.

    • Immune Checkpoint Inhibitors in Prostate Cancer.
    • Venkatachalam S, McFarland TR, Agarwal N, Swami U.
    • Cancers (Basel). 2021 May 2;13(9):2187. doi: 10.3390/cancers13092187.
    • SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
    • González Del Alba A, Méndez-Vidal MJ, Vazquez S, Castro E, Climent MA, Gallardo E, Gonzalez-Billalabeitia E, Lorente D, Maroto JP, Arranz JA.
    • Clin Transl Oncol. 2021 May;23(5):969-979. doi: 10.1007/s12094-021-02561-5. Epub 2021 Feb 24.
    • Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
    • Schettini F, Giudici F, Bernocchi O, Sirico M, Corona SP, Giuliano M, Locci M, Paris I, Scambia G, De Placido S, Rescigno P, Prat A, Curigliano G, Generali D.
    • Eur J Cancer. 2021 May;149:134-152. doi: 10.1016/j.ejca.2021.02.035. Epub 2021 Apr 13. Erratum in: Eur J Cancer. 2021 Aug;153:274.
    • Meta-Analysis
    • Aberrations of DNA repair pathways in prostate cancer: A cornerstone of precision oncology.
    • Boussios S, Rassy E, Shah S, Ioannidou E, Sheriff M, Pavlidis N.
    • Expert Opin Ther Targets. 2021 May;25(5):329-333. doi: 10.1080/14728222.2021.1951226. Epub 2021 Jul 8.
    • Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management.
    • Doan DK, Schmidt KT, Chau CH, Figg WD.
    • Cancers (Basel). 2021 Apr 29;13(9):2154. doi: 10.3390/cancers13092154.
    • Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.
    • Shore N, Ionescu-Ittu R, Yang L, Laliberté F, Mahendran M, Lejeune D, Yu L, Burgents J, Duh MS, Ghate SR.
    • Future Oncol. 2021 Apr 28. doi: 10.2217/fon-2021-0153. Epub ahead of print.
    • Distinct Response to Platinum-Based Chemotherapy Among Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    • Fan L, Fei X, Zhu Y, Chi C, Pan J, Sha J, Xin Z, Gong Y, Du X, Wang Y, Dong B, Xue W.
    • J Urol. 2021 Apr 27:101097JU0000000000001819. doi: 10.1097/JU.0000000000001819. Epub ahead of print.
    • The Quandary of DNA-Based Treatment Assessment in De Novo Metastatic Prostate Cancer in the Era of Precision Oncology.
    • Nakken S, Lilleby W, Switlyk MD, Knudsen KE, Lilleby O, Zhao S, Kaveh F, Ekstrøm PO, Urbanucci A, Hovig E.
    • J Pers Med. 2021 Apr 22;11(5):330. doi: 10.3390/jpm11050330.
    • Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    • Li N, Zheng H, Huang Y, Zheng B, Cai H, Liu M.
    • Front Pharmacol. 2021 Apr 20;12:632818. doi: 10.3389/fphar.2021.632818.
    • Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
    • Berchuck JE, Zhang Z, Silver R, Kwak L, Xie W, Lee GM, Freedman ML, Kibel AS, Van Allen EM, McKay RR, Taplin ME.
    • Eur Urol. 2021 Apr 19:S0302-2838(21)00237-2. doi: 10.1016/j.eururo.2021.03.031. Epub ahead of print.
    • Age-related activity of Poly (ADP-ribose) polymerase (PARP) in men with localized prostate cancer.
    • Deniz M, Zengerling F, Gundelach T, Moreno-Villanueva M, Bürkle A, Janni W, Bolenz C, Kostezka S, Marienfeld R, Benckendorff J, Friedl TWP, Wiesmüller L, Rall-Scharpf M.
    • Mech Ageing Dev. 2021 Apr 19:111494. doi: 10.1016/j.mad.2021.111494. Epub ahead of print.
    • Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer.
    • Staniszewska M, Iking J, Lückerath K, Hadaschik B, Herrmann K, Ferdinandus J, Fendler WP.
    • Nucl Med Biol. 2021 Apr 9;96-97:101-111. doi: 10.1016/j.nucmedbio.2021.03.009. Epub ahead of print.
    • Review
    • Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer.
    • Maughan BL, Antonarakis ES.
    • Expert Opin Pharmacother. 2021 Apr 7:1-8. doi: 10.1080/14656566.2021.1912015. Epub ahead of print.
    • Review
    • Changing the History of Prostate Cancer with New Targeted Therapies.
    • Hernando Polo S, Moreno Muñoz D, Rosero Rodríguez AC, Silva Ruiz J, Rosero Rodríguez DI, Couñago F.
    • Biomedicines. 2021 Apr 6;9(4):392. doi: 10.3390/biomedicines9040392.
    • Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention.
    • Vietri MT, D'Elia G, Caliendo G, Resse M, Casamassimi A, Passariello L, Albanese L, Cioffi M, Molinari AM.
    • Int J Mol Sci. 2021 Apr 4;22(7):3753. doi: 10.3390/ijms22073753.
    • Rare Germline Pathogenic Variants Identified by Multigene Panel Testing and the Risk of Aggressive Prostate Cancer.
    • Nguyen-Dumont T, Dowty JG, MacInnis RJ, Steen JA, Riaz M, Dugué PA, Renault AL, Hammet F, Mahmoodi M, Theys D, Tsimiklis H, Severi G, Bolton D, Lacaze P, Sebra R, Schadt E, McNeil J, Giles GG, Milne RL, Southey MC.
    • Cancers (Basel). 2021 Mar 24;13(7):1495. doi: 10.3390/cancers13071495.
    • Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
    • Gong J, Posadas E, Bhowmick N, Kim H, Daskivich T, Gupta A, Sandler H, Kamrava M, Zumsteg Z, Freedland S, Figlin R.
    • Oncology (Williston Park). 2021 Mar 15;35(3):119-125. doi: 10.46883/ONC.2021.3503.0119.
    • UK's NICE Does Not Recommend Lynparza for BRCA-Mutated Prostate Cancer.
    • [No author given]
    • GenomeWeb. Business & Policy. Regulatory News. 2021 Mar 5.
    • Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance.
    • Yu J, Cho E, Choi J, Lim JE, Lee J, Kang M, Sung HH, Jeong BC, Seo SI, Jeon SS, Lee HM, Jeon HG.
    • Investig Clin Urol. 2021 Mar;62(2):224-232. doi: 10.4111/icu.20200406.
    • Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States.
    • Santoni M, Cimadamore A, Massari F, Sorgentoni G, Cheng L, Lopez-Beltran A, Battelli N, Montironi R.
    • Transl Androl Urol. 2021 Mar;10(3):1562-1568. doi: 10.21037/tau-20-1439.
    • Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.
    • Pandya D, Shah M, Kaplan F, Martino C, Levy G, Kazanjian M, Batter S, Martignetti J, Frank RC.
    • Cold Spring Harb Mol Case Stud. 2021 Feb 19;7(1):a005801. doi: 10.1101/mcs.a005801.
    • Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease.
    • Saunders EJ, Kote-Jarai Z, Eeles RA.
    • Cancers (Basel). 2021 Feb 12;13(4):E760. doi: 10.3390/cancers13040760.
    • Benefit of AstraZeneca's Cediranib Plus Lynparza May Be Limited to HRR-Deficient Prostate Cancers.
    • Hopkins C.
    • Precision Oncology News. Cancer Specialties. 2021 Feb 12.
    • Conference news
    • Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
    • Tukachinsky H, Madison RW, Chung JH, Gjoerup OV, Severson EA, Dennis L, Fendler BJ, Morley S, Zhong L, Graf RP, Ross JS, Alexander BM, Abida W, Chowdhury S, Ryan CJ, Fizazi K, Golsorkhi T, Watkins SP, Simmons A, Loehr A, Venstrom JM, Oxnard GR.
    • Clin Cancer Res. 2021 Feb 8. doi: 10.1158/1078-0432.CCR-20-4805. Epub ahead of print.

    Related:

    Commentary, Review:

    Liquid Biopsy: It's the Bloody Truth!

    • Management of a Prostate Cancer Patient with inherited germline BRCA1 and BRCA2 mutations, a Case Report.
    • Hemal S, DeWitt-Foy M, Klein EA.
    • Urology. 2021 Feb 5:S0090-4295(21)00120-5. doi: 10.1016/j.urology.2020.11.076. Epub ahead of print.
    • Case report
    • Olaparib – cancer de prostate métastatique résistant à la castration muté BRCA [Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation].
    • Saillant A, Flippot R.
    • Bull Cancer. 2021 Feb 2:S0007-4551(21)00015-1. French. doi: 10.1016/j.bulcan.2020.11.010. Epub ahead of print.
    • Letter, [Article in French]
    • Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
    • Lozano R, Castro E, Aragón IM, Cendón Y, Cattrini C, López-Casas PP, Olmos D.
    • Br J Cancer. 2021 Feb;124(3):552-563. doi: 10.1038/s41416-020-01114-x. Epub 2020 Oct 27.
    • EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    • Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P.
    • Eur Urol. 2021 Feb;79(2):243-262. doi: 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7.
    • Guidelines, Review
    • FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer.
    • Anscher MS, Chang E, Gao X, Gong Y, Weinstock C, Bloomquist E, Adeniyi O, Charlab R, Zimmerman S, Serlemitsos-Day M, Ning YM, Mayrosh R, Fuller B, Trentacosti AM, Gallagher P, Bijwaard K, Philip R, Ghosh S, Fahnbulleh F, Diggs F, Arora S, Goldberg KB, Tang S, Amiri-Kordestani L, Pazdur R, Ibrahim A, Beaver JA.
    • Oncologist. 2021 Feb;26(2):139-146. doi: 10.1002/onco.13585. Epub 2020 Nov 17.
    • Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    • Su D, Wu B, Shi L.
    • Front Pharmacol. 2021 Jan 26;11:610601. doi: 10.3389/fphar.2020.610601.
    • Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
    • Lotan TL, Kaur HB, Salles DC, Murali S, Schaeffer EM, Lanchbury JS, Isaacs WB, Brown R, Richardson AL, Cussenot O, Cancel-Tassin G, Timms KM, Antonarakis ES.
    • Mod Pathol. 2021 Jan 18. doi: 10.1038/s41379-020-00731-4. Epub ahead of print.
    • Japanese Regulators Approve Lynparza for Ovarian, Prostate, Pancreatic Cancers.
    • [No author given]
    • Precision Oncology News. 2020 Dec 28.
    • Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort.
    • Ishiyama Y, Shimbo M, Iizuka J, Deshpande G, Tanabe K, Hattori K.
    • PLoS One. 2020 Dec 22;15(12):e0244149. doi: 10.1371/journal.pone.0244149.
    • Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors.
    • Chakraborty G, Khan Patail N, Hirani R, Nandakumar S, Mazzu YZ, Yoshikawa Y, Atiq MO, Jehane L, Stopsack KH, Lee GM, Abida W, Morris MJ, Mucci LA, Danila DC, Kantoff PW.
    • Clin Cancer Res. 2020 Dec 17:clincanres.2483.2020. doi: 10.1158/1078-0432.CCR-20-2483. Epub ahead of print.
    • Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated HRR Gene Alterations.
    • Shore N, Oliver L, Shui I, Gayle A, Wong OY, Kim J, Payne S, Amin S, Ghate S.
    • J Urol. 2020 Dec 17:101097JU0000000000001570. doi: 10.1097/JU.0000000000001570. Epub ahead of print.
    • PARP inhibitors in prostate cancer: practical guidance for busy clinicians.
    • VanderWeele DJ, Hussain M.
    • Clin Adv Hematol Oncol. 2020 Dec;18(12):808-815.
    • Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    • Jang A, Sartor O, Barata PC, Paller CJ.
    • Cancers (Basel). 2020 Nov 21;12(11):3467. doi: 10.3390/cancers12113467.
    • Beware Liquid Biopsies to Guide PARP Blockade.
    • [No author given]
    • Cancer Discov. 2020 Nov 18. doi: 10.1158/2159-8290.CD-NB2020-105. Epub ahead of print.
    • Research news
    • Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
    • Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg CN, Watkins SP, Despain D, Simmons AD, Loehr A, Dowson M, Golsorkhi T, Chowdhury S; TRITON2 investigators.
    • J Clin Oncol. 2020 Nov 10;38(32):3763-3772. doi: 10.1200/JCO.20.01035. Epub 2020 Aug 14.

    Related:

    Commentary:

    BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?

    • European Commission Green Lights Lynparza for Prostate, Ovarian Cancer Indications.
    • [No author given]
    • Precision Oncology News. 2020 Nov 5.
    • Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.
    • Gilson C, Ingleby F, Gilbert DC, Parry MA, Atako NB, Ali A, Hoyle A, Clarke NW, Gannon M, Wanstall C, Brawley C, Mason MD, Malik Z, Simmons A, Loehr A, Parry-Jones A, Eeles R, Kote-Jarai Z, James ND, Amos C, Parmar MKB, Langley RE, Sydes MR, Attard G, Chowdhury S; STAMPEDE Investigators.
    • JCO Precis Oncol. 2020 Nov;4:882-897. doi: 10.1200/PO.19.00388.
    • Case Report: Co-Existence of BRCA2 and PALB2 Germline Mutations in Familial Prostate Cancer With Solitary Lung Metastasis.
    • Tang T, Wang LA, Wang P, Tong D, Liu G, Zhang J, Dai N, Zhang Y, Yuan G, Geary K, Zhang D, Liu Q, Jiang J.
    • Front Oncol. 2020 Oct 26;10:564694. doi: 10.3389/fonc.2020.564694. PMID: 33194641; PMCID: PMC7649358.
    • Pulmonary metastasis secondary to abiraterone-resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case.
    • Izawa M, Kosaka T, Nakamura K, Oba J, Hishida T, Hongo H, Mikami S, Nishihara H, Oya M.
    • IJU Case Rep. 2020 Oct 15;4(1):14-17. doi: 10.1002/iju5.12224.
    • Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.
    • Sigorski D, Izycka-Swieszewska E, Bodnar L.
    • Target Oncol. 2020 Oct 12. doi: 10.1007/s11523-020-00756-4. Epub ahead of print.
    • Genetic biomarkers to guide poly (ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
    • Varnai R, Sipeky C.
    • Pharmacogenomics. 2020 Oct 6. doi: 10.2217/pgs-2020-0019. Epub ahead of print.
    • Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib.
    • Stopsack KH.
    • Eur Urol. 2020 Oct 1:S0302-2838(20)30716-8. doi: 10.1016/j.eururo.2020.09.024. Epub ahead of print.

    Related:

    Letter:

    Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.

    Letter:

    Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024 .

    • Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.
    • Schmid S, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen MCP, Beltran H, Conteduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh WK, Tsao CK, Sartor O, Ledet E, Di Lorenzo G, Yip SM, Chi KN, Bianchini D, De Giorgi U, Hansen AR, Beer TM, Lavaud P, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman AM, Le ML, Zürrer-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Gillessen S.
    • JAMA Netw Open. 2020 Oct 1;3(10):e2021692. doi: 10.1001/jamanetworkopen.2020.21692. Erratum in: JAMA Netw Open. 2020 Nov 2;3(11):e2029176.
    • Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
    • Carlson AS, Acevedo RI, Lim DM, Gulati R, Gawne A, Sokolova AO, Cheng HH, Nelson PS, Montgomery RB, Yu EY, Schweizer MT.
    • PLoS One. 2020 Sep 30;15(9):e0239686. doi: 10.1371/journal.pone.0239686.
    • Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer.
    • Slootbeek PHJ, Duizer ML, van der Doelen MJ, Kloots ISH, Kuppen MCP, Westgeest HM, Uyl-de Groot CA, Pamidimarri Naga S, Ligtenberg MJL, van Oort IM, Gerritsen WR, Schalken JA, Kroeze LI, Bloemendal HJ, Mehra N.
    • Int J Cancer. 2020 Sep 23. doi: 10.1002/ijc.33306. Epub ahead of print.
    • Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
    • Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroglu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators.
    • N Engl J Med. 2020 Sep 20. doi: 10.1056/NEJMoa2022485. Epub ahead of print.

    Related:

    Press, Conference report: Gene-Specific Exploratory Analysis Sheds Light on Lynparza Benefit in HRR-Mutated Prostate Cancer (Precision Oncology News)

    Press: EMA Committee Recommends Narrower Lynparza Indication for Metastatic Prostate Cancer Than FDA. (Precision Oncology News)

    • Gene-Specific Exploratory Analysis Sheds Light on Lynparza Benefit in HRR-Mutated Prostate Cancer.
    • Hopkins C.
    • Precision Oncology News. 2020 Sep 20.
    • Press, Conference report

    Related:

    Original research:

    Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

    • Poly (ADP-Ribose) Polymerase Inhibitor Activity in Prostate Cancers Harboring Mutations in DNA Repair Genes: Who Benefits?
    • Ganesan S, Garber J.
    • JCO Precis Oncol. 2020;4:1034. doi: 10.1200/PO.20.00269. Epub 2020 Sep 9.

    Related:

    Original research:

    Olaparib for Metastatic Castration-Resistant Prostate Cancer.

    Study record: Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study). (ClinicalTrials.gov)

    • Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment.
    • Schweizer MT, Cheng HH, Nelson PS, Montgomery RB.
    • J Clin Oncol. 2020 Sep 8:JCO2001755. doi: 10.1200/JCO.20.01755. Epub ahead of print.
    • Relaunched Canadian BRCA1/2 Screening Project Aims to ID High-Risk Carriers, Intervene Early.
    • Anderson A.
    • Precision Oncology News. 2020 Sep 8.
    • News
    • PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
    • Nizialek E, Antonarakis ES.
    • Cancer Manag Res. 2020 Sep 7;12:8105-8114. doi: 10.2147/CMAR.S227033.
    • BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications.
    • Messina C, Cattrini C, Soldato D, Vallome G, Caffo O, Castro E, Olmos D, Boccardo F, Zanardi E.
    • J Oncol. 2020 Sep 7;2020:4986365. doi: 10.1155/2020/4986365.
    • Genetic Testing for the Clinician in Prostate Cancer.
    • López Campos F, Linares-Espinós E, Maldonado Pijoan X, Sancho Pardo G, Morgan TM, Martínez-Ballesteros C, Martínez-Salamanca J, Couñago Lorenzo F.
    • Expert Rev Mol Diagn. 2020 Sep 4. doi: 10.1080/14737159.2020.1816170. Epub ahead of print.
    • Review
    • Invitae Launches Study to Explore Impact of Testing Guidelines on Prostate Cancer Patients' Outcomes.
    • [No author given]
    • Precision Oncology News. 2020 Sep 3.
    • Palmar Fasciitis and Polyarthritis Syndrome: A Rare Paraneoplastic Syndrome in a Patient With Prostate Carcinoma.
    • de Boer AG, Klaasen R, van der Goes MC, Bloemendal HJ.
    • J Med Cases. 2020 Sep;11(9):267-270. doi: 10.14740/jmc3522. Epub 2020 Aug 6.
    • Clinical implications of genomic evaluations for prostate cancer risk stratification, screening, and treatment: a narrative review.
    • Chung JS, Morgan TM, Hong SK.
    • Prostate Int. 2020 Sep;8(3):99-106. doi: 10.1016/j.prnil.2020.09.001. Epub 2020 Sep 14.
    • Germline mutations and prostate cancer: is it time to change treatment algorithms?
    • Telvizian T, Mukherji D.
    • Chin Clin Oncol. 2020 Aug 27:cco-19-207. doi: 10.21037/cco-19-207. Epub ahead of print.
    • Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer.
    • Chau V, Madan RA, Figg WD.
    • Cancer Biol Ther. 2020 Aug 26:1-4. doi: 10.1080/15384047.2020.1809913. Epub ahead of print.
    • When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    • Antonarakis ES, Gomella LG, Petrylak DP.
    • Eur Urol Oncol. 2020 Aug 17:S2588-9311(20)30096-1. doi: 10.1016/j.euo.2020.07.005. Epub ahead of print.
    • PARP Inhibitors & Prostate Cancer: To Infinity and Beyond BRCA.
    • Risdon EN, Chau CH, Price DK, Sartor O, Figg WD.
    • Oncologist. 2020 Aug 13. doi: 10.1634/theoncologist.2020-0697. Epub ahead of print.
    • Metastatic Castration-Resistant Prostate Cancer with Neuroendocrine Transformation and BRCA 1 Germ-Line Mutation: A Case Report and Literature Review.
    • Wu Y, Gao Y, Dou X, Yue J.
    • Onco Targets Ther. 2020 Aug 12;13:8049-8054. doi: 10.2147/OTT.S264347.
    • Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
    • Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E, Ghiringhelli F.
    • BMC Cancer. 2020 Aug 10;20(1):748. doi: 10.1186/s12885-020-07253-x.
    • Medicare to Cover Myriad Genetics' BRACAnalysis for FDA-Approved CDx Indications.
    • [No author given]
    • GenomeWeb. 2020 Jul 31.
    • PARP inhibitors in castration-resistant prostate cancer.
    • Tripathi A, Balakrishna P, Agarwal N.
    • Cancer Treat Res Commun. 2020 Jul 22;24:100199. doi: 10.1016/j.ctarc.2020.100199. Epub ahead of print.
    • Review
    • Epidemiology, Staging and Management of Prostate Cancer.
    • Barsouk A, Padala SA, Vakiti A, Mohammed A, Saginala K, Thandra KC, Rawla P, Barsouk A.
    • Med Sci (Basel). 2020 Jul 20;8(3):E28. doi: 10.3390/medsci8030028.
    • Targeting defective DNA repair in prostate cancer.
    • Carmichael J, Maza MLDF, Rescigno P, Chandran K, de Bono J.
    • Curr Opin Oncol. 2020 Jul 15. doi: 10.1097/CCO.0000000000000654. Epub ahead of print.
    • Review
    • Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
    • van der Doelen MJ, Isaacsson Velho P, Slootbeek PHJ, Pamidimarri Naga S, Bormann M, van Helvert S, Kroeze LI, van Oort IM, Gerritsen WR, Antonarakis ES, Mehra N.
    • Eur J Cancer. 2020 Jul 4;136:16-24. doi: 10.1016/j.ejca.2020.05.001. Epub ahead of print.
    • Update: PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer.
    • [No author given]
    • FORCE. XRAYS. 2020 Jun 1.

    Related:

    Drug Approval: FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer (U.S. Food & Drug Administration)

    • Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients.
    • Ray T.
    • Precision Oncology News. 2020 May 31.

    Related:

    Guidelines:

    Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).

    • FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer
    • [No author given]
    • GenomeWeb. 2020 May 20.
    • FDA Approves Olaparib for Certain Metastatic Prostate Cancers.
    • Mulcahy N.
    • Medscape. 2020 May 20.
    • FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer.
    • [No author given]
    • U.S. Food & Drug Administration. Drug Approvals. 2020 May 20.

    Related:

    News: Update: PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer (FORCE. XRAYS.)

    • First PARP Inhibitor Approved for Metastatic Prostate Cancer.
    • Nelson R.
    • Medscape. 2020 May 19.
    • Clovis Oncology's Rubraca Gets FDA Approval for BRCA-Mutated, Difficult-to-Treat Prostate Cancer.
    • [No author given]
    • Precision Oncology News. 2020 May 15.
    • FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer.
    • [No author given]
    • U.S Food & Drug Administration. 2020 May 15.

    Related:

    •• Press: First PARP Inhibitor Approved for Metastatic Prostate Cancer. (Medscape Oncology)

    • Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer.
    • Brönimann S, Lemberger U, Bruchbacher A, Shariat SF, Hassler MR.
    • Curr Opin Urol. 2020 May 13. doi: 10.1097/MOU.0000000000000776. Epub ahead of print.
    • Review
    • The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis.
    • Crumbaker M, Chan EKF, Gong T, Corcoran N, Jaratlerdsiri W, Lyons RJ, Haynes AM, Kulidjian AA, Kalsbeek AMF, Petersen DC, Stricker PD, Jamieson CAM, Croucher PI, Hovens CM, Joshua AM, Hayes VM.
    • Cancers (Basel). 2020 May 7;12(5):E1178. doi: 10.3390/cancers12051178.
    • PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.
    • Ratta R, Guida A, Scotté F, Neuzillet Y, Teillet AB, Lebret T, Beuzeboc P.
    • Prostate Cancer Prostatic Dis. 2020 May 4. doi: 10.1038/s41391-020-0233-3. [Epub ahead of print]
    • Review
    • Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
    • Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, Lara PN, Oesterreich S, Agarwal N, Necchi A, Miller VA, Alexander B, Ali SM, Ganesan S, Chung JH.
    • JCO Precis Oncol. 2020;4:442-465. doi: 10.1200/po.19.00345. Epub 2020 Apr 30.
    • Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    • de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M.
    • N Engl J Med. 2020 Apr 28. doi: 10.1056/NEJMoa1911440. [Epub ahead of print]
    • Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations.
    • Mota JM, Barnett E, Nauseef JT, Nguyen B, Stopsack KH, Wibmer A, Flynn JR, Heller G, Danila DC, Rathkopf D, Slovin S, Kantoff PW, Scher HI, Morris MJ, Schultz N, Solit DB, Abida W.
    • JCO Precis Oncol. 2020;4:355-366. doi: 10.1200/po.19.00346. Epub 2020 Apr 16.

    Related:

    Commentary:

    Re: Platinum-based Chemotherapy in Metastatic Prostate Cancer with DNA Repair Gene Alterations.

    Press: Prostate Cancer Patients With DNA Damage Repair Mutations May Respond to Platinum Chemo. (Precision Oncology News)

    • Myriad Genetics Seeks Japan Approval for Advanced Pancreatic, Prostate Cancer Companion Diagnostic.
    • [No author given]
    • GenomeWeb. 2020 Mar 30.
    • Short-Term Outcomes of Active Surveillance for Low-Risk Prostate Cancer Among Men with Germline DNA Repair Gene Mutations.
    • Halstuch D, Ber Y, Kedar D, Golan S, Baniel J, Margel D.
    • J Urol. 2020 Mar 19:101097JU0000000000001027. doi: 10.1097/JU.0000000000001027. [Epub ahead of print]
    • Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.
    • Wei Y, Wu J, Gu W, Wang J, Lin G, Qin X, Dai B, Gan H, Ye D, Zhu Y.
    • Oncologist. 2020 Mar 19. doi: 10.1634/theoncologist.2019-0495. [Epub ahead of print]
    • [Medical treatment options in BRCA-associated cancers].
    • Kahán Z.
    • Magy Onkol. 2020 Mar 17;64(1):13-24. Epub 2020 Feb 10.
    • Review, [Article in Hungarian]
    • Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
    • Simmons AD, Nguyen M, Pintus E.
    • BMC Cancer. 2020 Mar 14;20(1):215. doi: 10.1186/s12885-020-6657-2.
    • Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations.
    • Sztupinszki Z, Diossy M, Krzystanek M, Börcsök , Pomerantz MM, Tisza V, Spisák S, Rusz O, Csabai I, Freedman ML, Szallasi Z.
    • Clin Cancer Res. 2020 Feb 18. pii: clincanres.2135.2019. doi: 10.1158/1078-0432.CCR-19-2135. [Epub ahead of print]
    • BRCA2 and RB1 loss responds to PARP inhibitors.
    • Fenner A.
    • Nat Rev Urol. 2020 Feb 11. doi: 10.1038/s41585-020-0293-0. [Epub ahead of print]
    • Review
    • Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer.
    • Lotan TL, Tomlins SA, Bismar TA, Van der Kwast TH, Grignon D, Egevad L, Kristiansen G, Pritchard CC, Rubin MA, Bubendorf L.
    • Am J Surg Pathol. 2020 Feb 10. doi: 10.1097/PAS.0000000000001450. [Epub ahead of print]
    • Review
    • Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors.
    • Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan A, Brufksy AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M.
    • Clin Cancer Res. 2020 Feb 7. pii: clincanres.2933.2019. doi: 10.1158/1078-0432.CCR-19-2933. [Epub ahead of print]
    • Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report.
    • Julka PK, Verma A, Gupta K.
    • Case Rep Oncol. 2020 Feb 4;13(1):55-61. doi: 10.1159/000505182. eCollection 2020 Jan-Apr.
    • Genetic Testing in Prostate Cancer.
    • Sokolova AO, Cheng HH.
    • Curr Oncol Rep. 2020 Jan 23;22(1):5. doi: 10.1007/s11912-020-0863-6.
    • Review
    • Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.
    • Markowski MC, Shenderov E, Eisenberger MA, Kachhap S, Pardoll DM, Denmeade SR, Antonarakis ES.
    • Prostate. 2020 Jan 23. doi: 10.1002/pros.23955. [Epub ahead of print]
    • Case report
    • Myriad Genetics Files for FDA Approval of BRACAnalysis CDx for Lynparza in Prostate Cancer.
    • [No author given]
    • GenomeWeb. 2020 Jan 21.
    • Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy.
    • Cimadamore A, Lopez-Beltran A, Massari F, Santoni M, Mazzucchelli R, Scarpelli M, Galosi AB, Cheng L, Montironi R.
    • Future Oncol. 2020 Jan 9. doi: 10.2217/fon-2019-0745. [Epub ahead of print]
    • Review, Commentary
    • BRCA2 gene mutation and prostate cancer risk. Comprehensive review and update.
    • Saudi Med J. 2020 Jan;41(1):9-17. doi: 10.15537/smj.2020.1.24759.
    • [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    • Matveev VB, Kirichek AA, Filippova MG, Savinkova AV, Khalmurzaev OA, Lyubchenko LN.
    • Urologiia. 2019 Dec;(5):79-85.
    • [Article in Russian]
    • The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
    • van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS, Bergman AM, van Oort IM, de Wit R, Voest EE, Steeghs N, Yamaguchi TN, Livingstone J, Boutros PC, Martens JWM, Sleijfer S, Cuppen E, Zwart W, van de Werken HJG, Mehra N, Lolkema MP.
    • Nat Commun. 2019 Nov 20;10(1):5251. doi: 10.1038/s41467-019-13084-7.
    • Hereditary prostate cancer - Primetime for genetic testing?
    • Heidegger I, Tsaur I, Borgmann H, Surcel C, Kretschmer A, Mathieu R, Visschere P, Valerio M, van den Bergh RCN, Ost P, Tilki D, Gandaglia G, Ploussard G; EAU-YAU Prostate Cancer Working Party.
    • Cancer Treat Rev. 2019 Nov 11;81:101927. doi: 10.1016/j.ctrv.2019.101927. [Epub ahead of print]
    • Review
    • Olaparib to Change Practice in mCRPC.
    • [No authors listed]
    • Cancer Discov. 2019 Oct 24. doi: 10.1158/2159-8290.CD-NB2019-126. [Epub ahead of print]
    • Research news
    • A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation.
    • Kosaka T, Hongo H, Aimono E, Matsumoto K, Hayashida T, Mikami S, Nishihara H, Oya M.
    • Pathol Int. 2019 Oct 20. doi: 10.1111/pin.12860. [Epub ahead of print]
    • Patients resistant against PSMA-targeting alpha-radiation therapy often harbor mutations in DNA-repair associated genes.
    • Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, Bruchertseifer F, Kippenberger M, Rathke H, Leichsenring J, Hohenfellner M, Morgenstern A, Haberkorn U, Duensing S, Stenzinger A.
    • J Nucl Med. 2019 Oct 10. pii: jnumed.119.234559. doi: 10.2967/jnumed.119.234559. [Epub ahead of print]
    • Towards precision oncology in advanced prostate cancer.
    • Ku SY, Gleave ME, Beltran H.
    • Nat Rev Urol. 2019 Oct 7. doi: 10.1038/s41585-019-0237-8. [Epub ahead of print]
    • Review
    • 'Landmark' Trial in Prostate Cancer With Mutations.
    • Davenport L.
    • Medscape Oncology. 2019 Oct 4.
    • Molecular insights into the germline for prostate cancer initiation, progression, and aggressiveness.
    • Pritchard CC.
    • Can J Urol. 2019 Oct;26(5S2):24-26.
    • The BRCA2 mutation status shapes the immune phenotype of prostate cancer.
    • Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S.
    • Cancer Immunol Immunother. 2019 Sep 23. doi: 10.1007/s00262-019-02393-x. [Epub ahead of print]
    • Effect of DNA damage response mutations on prostate cancer prognosis: a systematic review.
    • Swift SL, Lang SH, White H, Misso K, Kleijnen J, Quek RG.
    • Future Oncol. 2019 Sep 19. doi: 10.2217/fon-2019-0298. [Epub ahead of print]
    • Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome.
    • Yadav S, Hart SN, Hu C, Hillman D, Lee KY, Gnanaolivu R, Na J, Polley EC, Couch FJ, Kohli M.
    • JCO Precis Oncol. 2019 Sep 17;3:PO.19.00067. doi: 10.1200/PO.19.00067.
    • Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
    • Petrovics G, Price DK, Lou H, Chen Y, Garland L, Bass S, Jones K, Kohaar I, Ali A, Ravindranath L, Young D, Cullen J, Dorsey TH, Sesterhenn IA, Brassell SA, Rosner IL, Ross D, Dahut W, Ambs S, Figg WD, Srivastava S, Dean M.
    • Prostate Cancer Prostatic Dis. 2019 Sep;22(3):406-410. doi: 10.1038/s41391-018-0114-1. Epub 2018 Dec 12.
    • Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
    • Adashek JJ, Jain RK, Zhang J.
    • Cells. 2019 Aug 9;8(8). pii: E860. doi: 10.3390/cells8080860.
    • Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    • Przybycinski J, Nalewajska M, Marchelek-Mysliwiec M, Dziedziejko V, Pawlik A.
    • Expert Opin Ther Targets. 2019 Aug 8. doi: 10.1080/14728222.2019.1654458. [Epub ahead of print]
    • Review
    • Myriad to Pursue mCRPC Approval for BRACAnalysis CDx
    • [No author given.]
    • Clinical Omics. 2019 Aug 7.
    • Myriad Genetics Seeking Additional FDA Approval for BRACAnalysis CDx.
    • [No author given]
    • GenomeWeb. 2019 Aug 7.
    • Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
    • Isaacsson Velho P, Qazi F, Hassan S, Carducci MA, Denmeade SR, Markowski MC, Thorek DL, DeWeese TL, Song DY, Tran PT, Eisenberger MA, Antonarakis ES.
    • Eur Urol. 2019 Aug;76(2):170-176. doi: 10.1016/j.eururo.2018.09.040. Epub 2018 Oct 4.
    • Bringing Prostate Cancer Germline Genetics into Clinical Practice.
    • Das S, Salami SS, Spratt DE, Kaffenberger SD, Jacobs MF, Morgan TM.
    • J Urol. 2019 Aug;202(2):223-230. doi: 10.1097/JU.0000000000000137. Epub 2019 Jul 8.
    • PARP Inhibitors in Prostate Cancer-The PreclinicalRationale and Current Clinical Development.
    • Virtanen V, Paunu K, Ahlskog JK, Varnai R, Sipeky C, Sundvall M.
    • Genes (Basel). 2019 Jul 26;10(8). pii: E565. doi: 10.3390/genes10080565.
    • Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.
    • Zhu J, Tucker M, Marin D, Gupta RT, Healy P, Humeniuk M, Jarvis C, Zhang T, McNamara M, George DJ, Wu Y, Lisi S, Armstrong AJ.
    • Urol Oncol. 2019 Jul 18. pii: S1078-1439(19)30244-3. doi: 10.1016/j.urolonc.2019.06.015. [Epub ahead of print]
    • Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.
    • Chatterjee P, Schweizer MT, Lucas JM, Coleman I, Nyquist MD, Frank SB, Tharakan R, Mostaghel E, Luo J, Pritchard CC, Lam HM, Corey E, Antonarakis ES, Denmeade SR, Nelson PS.
    • J Clin Invest. 2019 Jul 16;130. pii: 127613. doi: 10.1172/JCI127613.
    • Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.
    • Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, Ferreira A, Lambros MBK, Seed G, Yuan W, Dolling D, Welti JC, Neeb A, Sumanasuriya S, Rescigno , Bianchini D, Tunariu N, Carreira S, Sharp A, Oyen W, de Bono JS.
    • Eur Urol. 2019 Jul 13. pii: S0302-2838(19)30520-2. doi: 10.1016/j.eururo.2019.06.030. [Epub ahead of print]
    • 6-Thioguanine and Its Analogs Promote Apoptosis of Castration-Resistant Prostate Cancer Cells in a BRCA2-Dependent Manner.
    • Laera L, Guaragnella N, Giannattasio S, Moro L.
    • Cancers (Basel). 2019 Jul 5;11(7). pii: E945. doi: 10.3390/cancers11070945.
    • Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Prostate Cancer
    • Srinivas S, Shah SA.
    • NCCN Continuing Education. 2019 Jul 5.
    • CME Course
    • Somatic and germline sequencing in genitourinary oncology: genetics for the clinician.
    • Shoag JE, Wise DR, Sharaf RN, Sternberg CN.
    • Curr Opin Urol. 2019 Jul;29(4):315-318. doi: 10.1097/MOU.0000000000000643.
    • Review
    • Germline genetics in localized prostate cancer.
    • Ryan ST, Nguyen V, Bree KK, Holst DD, Kader AK.
    • Curr Opin Urol. 2019 Jul;29(4):326-333. doi: 10.1097/MOU.0000000000000648.
    • Review
    • Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    • Criscuolo D, Morra F, Giannella R, Cerrato A, Celetti A.
    • Int J Mol Sci. 2019 Jun 25;20(12). pii: E3100. doi: 10.3390/ijms20123100.
    • A Multidisciplinary Approach to Individualized Patient Care - Prostate Cancer: The Emerging Role of Tumor and Germline Genetic Testing and the Treatment of Advanced Disease.
    • Srinivas S, Shah SA.
    • National Comprehensive Cancer Network. Continuing Education. 2019 Jun 24.
    • CME course
    • Resolution Bioscience, Janssen Partner to Develop CDx for Niraparib in Prostate Cancer.
    • [No author given]
    • GenomeWeb. 2019 Jun 19.
    • Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer.
    • Fujiwara M, Akamatsu S, Sumiyoshi T, Segawa T, Mizuno K, Yoshino T, Goto T, Sawada A, Saito R, Kobayashi T, Yamasaki T, Inoue T, Ogawa O.
    • Clin Genitourin Cancer. 2019 Jun 12. pii: S1558-7673(19)30179-X. doi: 10.1016/j.clgc.2019.04.017. [Epub ahead of print]
    • Screening, Active Surveillance, and Treatment of Localized Prostate Cancer Among Carriers of Germline BRCA Mutations.
    • Halstuch D, Ber Y, Margel D.
    • Eur Urol Focus. 2019 May 27. pii: S2405-4569(19)30146-4. doi: 10.1016/j.euf.2019.05.009. [Epub ahead of print]
    • Review
    • Novel poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, AZD2461, down-regulates VEGF and induces apoptosis in prostate cancer cells.
    • Sargazi S, Saravani R, Zavar Reza J, Zarei Jaliani H, Galavi H, Liliya Viacheslavovna M, Abtahi NA.
    • Iran Biomed J. 2019 May 18. [Epub ahead of print]
    • Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.02.002.
    • Liang J, Beckta JM, Bindra RS.
    • Eur Urol. 2019 May 9. pii: S0302-2838(19)30358-6. doi: 10.1016/j.eururo.2019.04.041. [Epub ahead of print]
    • Letter, Commentary

    Related:

    Original research:

    Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.

    • Germline and Somatic Mutations in Prostate Cancer for the Clinician.
    • Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS.
    • J Natl Compr Canc Netw. 2019 May 1;17(5):515-521. doi: 10.6004/jnccn.2019.7307.
    • DNA repair defects in prostate cancer: impact for screening, prognostication and treatment.
    • Warner EW, Yip SM, Chi KN, Wyatt AW.
    • BJU Int. 2019 May;123(5):769-776. doi: 10.1111/bju.14576. Epub 2018 Oct 26.
    • Review
    • Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    • Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K, Na R, Shi Z, Petkewicz J, Shah S, Fantus RJ, Novakovic K, Brendler CB, Zheng SL, Isaacs WB, Xu J.
    • Eur Urol. 2019 May;75(5):743-749. doi: 10.1016/j.eururo.2018.09.021. Epub 2018 Oct 8.

    Related:

    Research news: DNA-Repair- Gene Mutations Linked to More Aggressive Prostate Cancer. (Medscape Oncology)

    • DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.
    • Lotan TL, Kaur HB, Alharbi AM, Pritchard CC, Epstein JI.
    • Histopathology. 2019 May;74(6):836-843. doi: 10.1111/his.13806. Epub 2019 Apr 1.
    • The influence of BRCA2 mutation on localized prostate cancer.
    • Taylor RA, Fraser M, Rebello RJ, Boutros PC, Murphy DG, Bristow RG, Risbridger GP.
    • Nat Rev Urol. 2019 May;16(5):281-290. doi: 10.1038/s41585-019-0164-8.
    • Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
    • Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan C, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN; PCCTC Germline Genetics Working Group.
    • Clin Genitourin Cancer. 2019 Apr 18. pii: S1558-7673(19)30139-9. doi: 10.1016/j.clgc.2019.04.013. [Epub ahead of print]
    • Myriad Genetics Expands CDx Collaboration with AstraZeneca, Merck & Co.
    • [No author given.]
    • Clinical Omics. 2019 Apr 4.
    • Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance.
    • Horak P, Weischenfeldt J, von Amsberg G, Beyer B, Schütte A, Uhrig S, Gieldon L, Klink B, Feuerbach L, Hübschmann D, Kreutzfeldt S, Heining C, Maier S, Hutter B, Penzel R, Schlesner M, Eils R, Sauter G, Stenzinger A, Brors B, Schröck E, Glimm H, Fröhling S, Schlomm T.
    • Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003657. doi: 10.1101/mcs.a003657. Print 2019 Apr.
    • A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
    • Köcher S, Beyer B, Lange T, Nordquist L, Volquardsen J, Burdak-Rothkamm S, Schlomm T, Petersen C, Rothkamm K, Mansour WY.
    • Int J Cancer. 2019 Apr 1;144(7):1685-1696. doi: 10.1002/ijc.32018. Epub 2019 Jan 5.
    • Evolving Role of Genomics in Genitourinary Neoplasms.
    • Devitt ME, Dreicer R.
    • Acta Med Acad. 2019 Apr;48(1):68-77. doi: 10.5644/ama2006-124.243.
    • Niraparib Shrinks BRCA-Mutated Prostate Tumors.
    • [No authors listed]
    • Cancer Discov. 2019 Apr;9(4):OF7. doi: 10.1158/2159-8290.CD-NB2019-030. Epub 2019 Mar 1.
    • Research News
    • BRCAness in prostate cancer.
    • Bednarz-Knoll N, Eltze E, Semjonow A, Brandt B.
    • Oncotarget. 2019 Mar 29;10(25):2421-2422. doi: 10.18632/oncotarget.26818. eCollection 2019 Mar 29.
    • Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
    • Athie A, Arce-Gallego S, Gonzalez M, Morales-Barrera R, Suarez C, Casals Galobart T, Hernandez Viedma G, Carles J, Mateo J.
    • Curr Oncol Rep. 2019 Mar 27;21(5):42. doi: 10.1007/s11912-019-0790-6.
    • Review
    • The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
    • Oh M, Alkhushaym N, Fallatah S, Althaghfi A, Aljadeed R, Alsowaida Y, Jeter J, Martin JR, Babiker HM, McBride A, Abraham I.
    • Prostate. 2019 Mar 22. doi: 10.1002/pros.23795. [Epub ahead of print]
    • Meta-Analysis
    • BRCA2 and Other DDR Genes in Prostate Cancer.
    • Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E.
    • Cancers (Basel). 2019 Mar 12;11(3). pii: E352. doi: 10.3390/cancers11030352.
    • Targeting the lysosome by an aminomethylated Riccardin D triggers DNA damage through cathepsin B-mediated degradation of BRCA1.
    • Wang Y, Niu H, Hu Z, Zhu M, Wang L, Han L, Qian L, Tian K, Yuan H, Lou H.
    • J Cell Mol Med. 2019 Mar;23(3):1798-1812. doi: 10.1111/jcmm.14077. Epub 2018 Dec 18.
    • Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response.
    • Zhang W, van Weerden WM, de Ridder CMA, Erkens-Schulze S, Schönfeld E, Meijer TG, Kanaar R, van Gent DC, Nonnekens J.
    • Prostate. 2019 Mar;79(4):390-402. doi: 10.1002/pros.23745. Epub 2018 Dec 5.
    • Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage.
    • Marshall CH, Fu W, Wang H, Baras AS, Lotan TL, Antonarakis ES.
    • Prostate Cancer Prostatic Dis. 2019 Mar;22(1):59-65. doi: 10.1038/s41391-018-0086-1. Epub 2018 Aug 31.
    • Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    • Marshall CH, Sokolova AO, McNatty AL, Cheng HH, Eisenberger MA, Bryce AH, Schweizer MT, Antonarakis ES.
    • Eur Urol. 2019 Feb 20. pii: S0302-2838(19)30110-1. doi: 10.1016/j.eururo.2019.02.002. [Epub ahead of print]
    • PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
    • Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R, Gonzalez-Billalabeitia E, Cendón Y, García-Carbonero I, Borrega P, Mendez Vidal MJ, Montesa A, Nombela P, Fernández-Parra E, Gonzalez Del Alba A, Villa-Guzmán JC, Ibáñez K, Rodriguez-Vida A, Magraner-Pardo L, Perez-Valderrama B, Vallespín E, Gallardo E, Vazquez S, Pritchard CC, Lapunzina P, Olmos D.
    • J Clin Oncol. 2019 Feb 20;37(6):490-503. doi: 10.1200/JCO.18.00358. Epub 2019 Jan 9.
    • Metastatic Prostate Cancer: Effects of Genetic Testing on Care.
    • Connors LM.
    • Clin J Oncol Nurs. 2019 Feb 1;23(1):32-35. doi: 10.1188/19.CJON.32-35.
    • Review
    • Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.
    • Omari A, Nastały P, Stoupiec S, Bałabas A, Dąbrowska M, Bielińska B, Huss S, Pantel K, Semjonow A, Eltze E, Brandt B, Bednarz-Knoll N.
    • Int J Cancer. 2019 Feb 1;144(3):607-614. doi: 10.1002/ijc.31905. Epub 2018 Oct 22.
    • Tumor Lysis Syndrome After Platinum-based Chemotherapy in Castration-resistant Prostate Cancer With a BRCA2 Mutation: A Case Report.
    • Gongora ABL, Canedo FSNA, de Melo ALA, Bezerra ROF, Asprino PF, Camargo AA, Bastos DA.
    • Clin Genitourin Cancer. 2019 Feb;17(1):e61-e64. doi: 10.1016/j.clgc.2018.09.001. Epub 2018 Sep 7.
    • The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.
    • Pilarski R.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):79-86. doi: 10.1200/EDBK_238977.
    • Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
    • Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.
    • Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16.
    • Review
    • Germline and Somatic Defects in DNA Repair Pathways in Prostate Cancer.
    • Arce S, Athie A, Pritchard CC, Mateo J.
    • Adv Exp Med Biol. 2019;1210:279-300. doi: 10.1007/978-3-030-32656-2_12.
    • Review, Book chapter
    • Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
    • Petrovics G, Price DK, Lou H, Chen Y, Garland L, Bass S, Jones K, Kohaar I, Ali A, Ravindranath L, Young D, Cullen J, Dorsey TH, Sesterhenn IA, Brassell SA, Rosner IL, Ross D, Dahut W, Ambs S, Figg WD, Srivastava S, Dean M.
    • Prostate Cancer Prostatic Dis. 2018 Dec 12. doi: 10.1038/s41391-018-0114-1. [Epub ahead of print]
    • Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.
    • Fenerty KE, Padget M, Wolfson B, Gameiro SR, Su Z, Lee JH, Rabizadeh S, Soon-Shiong P, Hodge JW.
    • J Immunother Cancer. 2018 Nov 29;6(1):133. doi: 10.1186/s40425-018-0445-4.
    • Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
    • Ma Y, He L, Huang Q, Zheng S, Zhang Z, Li H, Liu S.
    • BMC Med Genet. 2018 Oct 17;19(1):185. doi: 10.1186/s12881-018-0703-9.
    • A Devastatingly "Minor" Relationship Between Male Breast Cancer and Prostate Cancer.
    • Kolli S, Asarian A, Genato R, Xiao P.
    • Cureus. 2018 Oct 17;10(10):e3463. doi: 10.7759/cureus.3463.
    • [DNA damage repair: An emerging strategy in metastatic prostate cancer].
    • Loriot Y, Meynard G, Klajer E, Bolognini C, Gassian N, Thiery-Vuillemin A.
    • Bull Cancer. 2018 Oct;105(10):944-954. doi: 10.1016/j.bulcan.2018.05.017. Epub 2018 Sep 29.
    • Review, [Article in French]
    • Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?
    • Caffo O, Veccia A, Kinspergher S, Rizzo M, Maines F.
    • Front Cell Dev Biol. 2018 Sep 5;6:71. doi: 10.3389/fcell.2018.00071. eCollection 2018.
    • Prostate Cancer Germline Variations and Implications for Screening and Treatment.
    • Dias A, Kote-Jarai Z, Mikropoulos C, Eeles R.
    • Cold Spring Harb Perspect Med. 2018 Sep 4;8(9). pii: a030379. doi: 10.1101/cshperspect.a030379.
    • Review
    • Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?
    • Di Nunno V, Santoni M, Massari F.
    • Lancet Oncol. 2018 Sep;19(9):e437-e438. doi: 10.1016/S1470-2045(18)30458-3.

    Related:

    Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.

    Letter, Reply: Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer? – Authors' reply (Lancet Oncology)

    • A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy.
    • Liu Q, Tong D, Liu G, Yi Y, Xu J, Yang X, Wang L, Zhang J, Ye J, Zhang Y, Yuan G, Wang P, Chen R, Guan Y, Yi X, Zhang D, Jiang J.
    • Cancer Biol Ther. 2018 Aug 3;19(8):669-675. doi: 10.1080/15384047.2018.1451278. Epub 2018 Apr 19.
    • Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
    • Frank S, Nelson P, Vasioukhin V.
    • F1000Res. 2018 Aug 2;7. pii: F1000 Faculty Rev-1173. doi: 10.12688/f1000research.14499.1. eCollection 2018.
    • BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy.
    • Ahmadzadehfar H, Gaertner F, Lossin PS1, Schwarz B, Essler M.
    • Clin Nucl Med. 2018 Aug;43(8):609-610. doi: 10.1097/RLU.0000000000002141.
    • Case report
    • Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    • Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, Silberstein JL, Piana D, Lai Z, Chen Y, Isaacs WB, Luo J.
    • Eur Urol. 2018 Aug;74(2):218-225. doi: 10.1016/j.eururo.2018.01.035. Epub 2018 Feb 10.
    • DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
    • Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ.
    • J Natl Compr Canc Netw. 2018 Aug;16(8):933-937. doi: 10.6004/jnccn.2018.7020.
    • Molecular correlates of intermediate- and high-risk localized prostate cancer.
    • Ye H, Sowalsky AG.
    • Urol Oncol. 2018 Aug;36(8):368-374. doi: 10.1016/j.urolonc.2017.12.022. Epub 2018 Mar 2.
    • Review
    • The resounding effect of DNA repair deficiency in prostate cancer.
    • Cheng HH.
    • Urol Oncol. 2018 Aug;36(8):385-388. doi: 10.1016/j.urolonc.2018.02.014. Epub 2018 Mar 17.
    • Review
    • DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC).
    • Rathi N, Anderson N, Greenberg S, Vagher J, Agarwal N, Hahn AW.
    • World J Oncol. 2018 Aug;9(4):119-122. doi: 10.14740/wjon1144w. Epub 2018 Sep 6.
    • PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
    • Yin L, Liu Y, Peng Y, Peng Y, Yu X, Gao Y, Yuan B, Zhu Q, Cao T, He L, Gong Z, Sun L, Fan X, Li X.
    • J Exp Clin Cancer Res. 2018 Jul 16;37(1):153. doi: 10.1186/s13046-018-0810-7.
    • Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer.
    • Chanez B, Chaffanet M, Adélaide J, Thomassin J, Garnier S, Carbuccia N, Guille A, Charrier N, Brenot-Rossi I, Walz J, Pignot G, Pakradouni J, Gonçalvès A, Eisinger F, Bertucci F, Birnbaum D, Gravis G.
    • JCO Precis Oncol. 2018 Nov [Epub 2018 Jul 10];2:1-8. doi: 10.1200/PO.18.00083.
    • Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.
    • Boudadi K, Suzman DL, Anagnostou V, Fu W, Luber B, Wang H, Niknafs N, White JR, Silberstein JL, Sullivan R, Dowling D, Harb R, Nirschl TR, Veeneman BA, Tomlins SA, Wang Y, Jendrisak A, Graf RP, Dittamore R, Carducci MA, Eisenberger MA, Haffner MC, Meeker AK, Eshleman JR, Luo J, Velculescu VE, Drake CG, Antonarakis ES.
    • Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564. eCollection 2018 Jun 19.
    • Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise.
    • Sumanasuriya S, De Bono J.
    • Cold Spring Harb Perspect Med. 2018 Jun 1;8(6). pii: a030635. doi: 10.1101/cshperspect.a030635.
    • Molecular Subtypes of Prostate Cancer.
    • Arora K, Barbieri CE.
    • Curr Oncol Rep. 2018 Jun 1;20(8):58. doi: 10.1007/s11912-018-0707-9.
    • Review
    • Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer.
    • Cheng H, Powers J, Schaffer K, Sartor O.
    • Am Soc Clin Oncol Educ Book. 2018 May 23;(38):372-381. doi: 10.1200/EDBK_205441.
    • Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.
    • Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V, Kolinsky M, Balasopoulou A, Bertan C, Nanus DM, Tagawa ST, Thorne H, Montgomery B, Carreira S, Sandhu S, Rubin MA, Nelson PS, de Bono JS.
    • Eur Urol. 2018 May;73(5):687-693. doi: 10.1016/j.eururo.2018.01.010. Epub 2018 Feb 8.
    • Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
    • Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN.
    • Cancer Discov. 2018 Apr;8(4):444-457. doi: 10.1158/2159-8290.CD-17-0937. Epub 2018 Jan 24.

    Related:

    Research news:

    Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test.

    • DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223.
    • Ramos JD, Mostaghel EA, Pritchard CC, Yu EY.
    • Clin Genitourin Cancer. 2018 Apr;16(2):106-110. doi: 10.1016/j.clgc.2017.11.009. Epub 2017 Dec 6.
    • PARP1-siRNA suppresses human prostate cancer cell growth and progression.
    • Lai Y, Kong Z, Zeng T, Xu S, Duan X, Li S, Cai C, Zhao Z, Wu W.
    • Oncol Rep. 2018 Apr;39(4):1901-1909. doi: 10.3892/or.2018.6238. Epub 2018 Jan 26.
    • Germline BRCA mutation in male carriers-ripe for precision oncology?
    • Leão RRN, Price AJ, James Hamilton R.
    • Prostate Cancer Prostatic Dis. 2018 Apr;21(1):48-56. doi: 10.1038/s41391-017-0018-5. Epub 2017 Dec 14.
    • Review
    • NCCN Updated Prostate Cancer Guidelines Include New Genetic Testing Information.
    • [No author given]
    • Precision Oncology News. Diagnostics. 2018 Feb 20.
    • Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.
    • Carneiro BA, Collier KA, Nagy RJ, Pamarthy S, Sagar V, Fairclough S, Odegaard J, Lanman RB, Costa R, Taxter T, Kuzel TM, Fan A, Chae YK, Cristofanilli M, Hussain MH, Abdulkadir SA, Giles FJ.
    • JCO Precis Oncol. 2018;2:PO.17.00176. doi: 10.1200/PO.17.00176. Epub 2018 Feb 14.

    Related:

    Commentary:

    Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum.

    Case report:

    Polyclonal BRCA2 Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer.

    • Tumor Suppressor Tolerance: Reversion Mutations in BRCA1 and BRCA2 and Resistance to PARP Inhibitors and Platinum.
    • Ganesan S.
    • JCO Precis Oncol. 2018 Nov [2018 Feb 14];2:1-4. doi: 10.1200/PO.18.00001.

    Related:

    Case report:

    Somatic Reversion of Germline BRCA2 Mutation Confers Resistance to Poly(ADP-ribose) Polymerase Inhibitor Therapy.

    Case report:

    Polyclonal BRCA2 Reversion Mutations Detected in Circulating Tumor DNA After Platinum Chemotherapy in a Patient With Metastatic Prostate Cancer.

    Original research:

    Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.

    • Men with a susceptibility to prostate cancer and the role of genetic based screening.
    • Eeles R, Ni Raghallaigh H.
    • Transl Androl Urol. 2018 Feb;7(1):61-69. doi: 10.21037/tau.2017.12.30.
    • BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy.
    • Conteduca V, Sigouros M, Sboner A, Pritchard CC, Beltran H.
    • JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00115. Epub 2018 Jun 29.
    • Olaparib.
    • Bochum S, Berger S, Martens UM.
    • Recent Results Cancer Res. 2018;211:217-233. doi: 10.1007/978-3-319-91442-8_15.
    • Review
    • [Prostate cancer and DNA repair genes].
    • Penel N.
    • Bull Cancer. 2017 Nov;104(11):958-961. doi: 10.1016/j.bulcan.2017.07.005. Epub 2017 Oct 9.
    • Letter, [Article in French]
    • A Novel Use for Olaparib for Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    • Martin GA, Chen AH, Parikh K.
    • Pharmacotherapy. 2017 Nov;37(11):1406-1414. doi: 10.1002/phar.2027.
    • Review
    • Combining Enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness.
    • Thompson TC, Li L, Broom BM.
    • Oncotarget. 2017 Oct 25. doi: 10.18632/oncotarget.22074. [Epub ahead of print]
    • Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    • Özdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK.
    • Eur Urol Focus. 2017 Oct 19. pii: S2405-4569(17)30238-9. doi: 10.1016/j.euf.2017.10.001. [Epub ahead of print]
    • Review
    • The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
    • Pomerantz MM, Spisák S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O'Connor EP, Herbert ZT, Szállási Z, Oh WK, Kantoff PW, Garber JE, Schrag D, Kibel AS, Freedman ML.
    • Cancer. 2017 Sep 15;123(18):3532-3539. doi: 10.1002/cncr.30808. Epub 2017 Jun 13.

    Related:

    Editorial:

    Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-Mutated prostate cancers.

    • Analysis of Circulating Cell-free DNA Identifies Multi-clonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
    • Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard CC, Thomas GV, Tomlins SA, Knudsen KE, Lord CJ, Ryan CJ, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY.
    • Cancer Discov. 2017 Sep;7(9):999-1005. doi: 10.1158/2159-8290.CD-17-0146. Epub 2017 Apr 27.

    Related:

    Review:

    Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.

    • Circulating Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
    • Goodall J, Mateo J, Yuan W, Mossop H, Porta N, Miranda S, Perez-Lopez R, Dolling D, Robinson DR, Sandhu S, Fowler G, Ebbs B, Flohr P, Seed G, Nava Rodrigues D, Boysen G, Bertan C, Atkin M, Clarke M, Crespo M, Figueiredo I, Riisnaes R, Sumanasuriya S, Rescigno P, Zafeiriou Z, Sharp A, Tunariu N, Bianchini D, Gillman A, Lord CJ, Hall E, Chinnaiyan AM, Carreira S, de Bono JS.
    • Cancer Discov. 2017 Sep;7(9):1006-1017. doi: 10.1158/2159-8290.CD-17-0261. Epub 2017 Apr 27.

    Related:

    Research news:

    New blood test could extend prostate cancer survival.

    Review:

    Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.

    Press: New three-in-one blood test opens door to precision medicine for prostate cancer. (MedicalXpress)

    • Commentary on "Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer". Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Eur Urol. Jun 2016;69(6):992-5.
    • Freedland S, Aronson W.
    • Urol Oncol. 2017 Aug;35(8):536. doi: 10.1016/j.urolonc.2017.05.011. Epub 2017 Jun 13.
    • Commentary

    Related:

    Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.

    • Mutations in BRCA2 and taxane resistance in prostate cancer.
    • Nientiedt C, Heller M, Endris V, Volckmar AL, Zschäbitz S, Tapia-Laliena MA, Duensing A, Jäger D, Schirmacher P, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.
    • Sci Rep. 2017 Jul 4;7(1):4574. doi: 10.1038/s41598-017-04897-x.
    • Relevance of DNA damage repair in the management of prostate cancer.
    • Banks P, Xu W, Murphy D, James P, Sandhu S.
    • Curr Probl Cancer. 2017 Jul - Aug;41(4):287-301. doi: 10.1016/j.currproblcancer.2017.06.001. Epub 2017 Jun 27.
    • Review
    • Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
    • Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW.
    • Eur Urol. 2017 Jul;72(1):34-42. doi: 10.1016/j.eururo.2017.02.023. Epub 2017 Mar 1.
    • Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.
    • Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, Arcila ME, Zehir A, Syed A, Gao J, Chakravarty D, Vargas HA, Robson ME, Joseph V, Offit K, Donoghue MTA, Abeshouse AA, Kundra R, Heins ZJ, Penson AV, Harris C, Taylor BS, Ladanyi M, Mandelker D, Zhang L, Reuter VE, Kantoff PW, Solit DB, Berger MF, Sawyers CL, Schultz N, Scher HI.
    • JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00029. Epub 2017 May 31.
    • Intraductal Carcinoma of the Prostate: A Risk for Rapid Recurrence.
    • Dinerman BF, Bernstein AN, Khani F, Hu JC.
    • Urology. 2017 Jul;105:e1-e2. doi: 10.1016/j.urology.2017.03.030. Epub 2017 Mar 28.
    • Review
    • BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer.
    • Cui M, Gao XS, Gu X, Guo W, Li X, Ma M, Qin S, Qi X, Xie M, Peng C, Bai Y.
    • Oncotarget. 2017 Jun 20;8(25):40222-40232. doi: 10.18632/oncotarget.16712.
    • PARP Inhibitors in Prostate Cancer.
    • Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK.
    • Curr Treat Options Oncol. 2017 Jun;18(6):37. doi: 10.1007/s11864-017-0480-2.
    • Review
    • Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
    • Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC.
    • Sci Signal. 2017 May 23;10(480). pii: eaam7479. doi: 10.1126/scisignal.aam7479.

    Related:

    Research news: Expanding the use of PARP inhibitors. (Nature Reviews Cancer)

    • 5 Big Questions (and Answers) on Inherited Prostate Cancer Testing.
    • Nick Mulcahy
    • Medscape. Coverage from the American Urological Association (AUA) 2017 Annual Meeting. 2017 May 18.
    • Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient.
    • Romero-Laorden N, Piñeiro-Yañez E, Gutierrez-Pecharroman A, Pacheco MI, Calvo E, Al-Shahrour F, Castro E, Olmos D1.
    • Ann Oncol. 2017 May 1;28(5):1158-1159. doi: 10.1093/annonc/mdx067.
    • Letter, Case report
    • Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer.
    • Purshouse K, Schuh A, Fairfax BP, Knight S, Antoniou P, Dreau H, Popitsch N, Gatter K, Roberts I, Browning L, Traill Z, Kerr D, Verrill C, Tuthill M, Taylor JC, Protheroe A.
    • Cold Spring Harb Mol Case Stud. 2017 May;3(3):a001362. doi: 10.1101/mcs.a001362.
    • EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    • Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RC, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P.
    • Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.
    • Conference Report, Review
    • Changing face of metastatic prostate cancer: the law of diminishing returns holds true.
    • Vaishampayan UN.
    • Curr Opin Oncol. 2017 Mar 18. doi: 10.1097/CCO.0000000000000370. [Epub ahead of print]
    • Review
    • Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
    • De Felice F, Tombolini V, Marampon F, Musella A, Marchetti C.
    • Drug Des Devel Ther. 2017 Mar 1;11:547-552. doi: 10.2147/DDDT.S110264. eCollection 2017.
    • Prostate cancer heterogeneity: Discovering novel molecular targets for therapy.
    • Ciccarese C, Massari F, Iacovelli R, Fiorentino M, Montironi R, Di Nunno V, Giunchi F, Brunelli M, Tortora G.
    • Cancer Treat Rev. 2017 Mar;54:68-73. doi: 10.1016/j.ctrv.2017.02.001. Epub 2017 Feb 11.
    • Review
    • DNA Repair in Prostate Cancer: Biology and Clinical Implications.
    • Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS.
    • Eur Urol. 2017 Mar;71(3):417-425. doi: 10.1016/j.eururo.2016.08.037. Epub 2016 Aug 31.
    • Extreme Response to High-dose Testosterone in BRCA2- and ATM-mutated Prostate Cancer.
    • Teply BA, Kachhap S, Eisenberger MA, Denmeade SR.
    • Eur Urol. 2017 Mar;71(3):499. doi: 10.1016/j.eururo.2016.09.020. Epub 2016 Sep 29.
    • Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
    • Li J, Wang R, Kong Y, Broman MM, Carlock C, Chen L, Li Z, Farah E, Ratliff TL, Liu X.
    • Mol Cancer Ther. 2017 Mar;16(3):469-479. doi: 10.1158/1535-7163.MCT-16-0361. Epub 2017 Jan 9.
    • Exceptional Duration of Radium-223 in Prostate Cancer With a BRCA2 Mutation.
    • Steinberger AE, Cotogno P, Ledet EM, Lewis B, Sartor O.
    • Clin Genitourin Cancer. 2017 Feb;15(1):e69-e71. doi: 10.1016/j.clgc.2016.09.001. Epub 2016 Sep 17.
    • Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
    • Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG.
    • Nat Commun. 2017 Jan 9;8:13671. doi: 10.1038/ncomms13671.

    Related:

    Research News:

    Prostate cancer: Genomic drivers of BRCA2-mutant tumours.

    • PARP inhibition in BRCA2-mutated prostate cancer.
    • Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.
    • Ann Oncol. 2017 Jan 1;28(1):189-191. doi: 10.1093/annonc/mdw445.
    • PARP inhibitors and stratified treatment of prostate cancer.
    • Lavery A, Gilson C, Chowdhury S.
    • Expert Rev Anticancer Ther. 2016 Dec;16(12):1213-1215. Epub 2016 Oct 17.
    • Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.
    • Buonerba C, Di Lorenzo G, Sonpavde G.
    • Expert Rev Mol Diagn. 2016 Oct;16(10):1113-1120. Epub 2016 Sep 28.
    • Review
    • Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer.
    • Modena A, Iacovelli R, Scarpa A, Brunelli M, Ciccarese C, Fantinel E, Bimbatti D, Massari F, Martignoni G, Tortora G.
    • Target Oncol. 2016 Oct;11(5):569-577.
    • Review
    • Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
    • Castro E, Mateo J, Olmos D, de Bono JS.
    • Cancer J. 2016 Sep/Oct;22(5):353-356.
    • Review
    • Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers.
    • Gleicher S, Kauffman EC, Kotula L, Bratslavsky G, Vourganti S.
    • Prostate. 2016 Sep;76(13):1135-45. doi: 10.1002/pros.23204. Epub 2016 May 26.
    • Meta-Analysis, Review
    • DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    • Dhawan M, Ryan CJ, Ashworth A.
    • Oncologist. 2016 Aug;21(8):940-5. doi: 10.1634/theoncologist.2016-0135. Epub 2016 Jun 17.
    • Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.
    • Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B.
    • Eur Urol. 2016 Jun;69(6):992-5. doi: 10.1016/j.eururo.2015.11.022. Epub 2015 Dec 24.

    Related:

    Commentary:

    Commentary on "Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer". Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Eur Urol. Jun 2016;69(6):992-5.

    • The Clinical Impact of BRCA2 Loss in Prostate Cancer.
    • Bryant HE.
    • Eur Urol. 2016 Jun;69(6):996-7. doi: 10.1016/j.eururo.2015.12.009. Epub 2015 Dec 18.
    • Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.
    • Decker B, Karyadi DM, Davis BW, Karlins E, Tillmans LS, Stanford JL, Thibodeau SN, Ostrander EA.
    • Am J Hum Genet. 2016 May 5;98(5):818-829. doi: 10.1016/j.ajhg.2016.03.003. Epub 2016 Apr 14.
    • PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations.
    • Helleday T.
    • Ann Oncol. 2016 May;27(5):755-7. doi: 10.1093/annonc/mdw048. Epub 2016 Feb 9.
    • Editorial
    • Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
    • Palmbos PL, Hussain MH.
    • Oncology (Williston Park). 2016 May;30(5). pii: 217036.

    Related:

    Comment:

    PARP Inhibition in Prostate Cancer: A Promising Approach.

    • Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer.
    • Chedgy EC, Annala M, Beja K, Warner EW, Gleave ME, Chi KN, Wyatt AW.
    • Clin Genitourin Cancer. 2016 Apr;14(2):e233-6. doi: 10.1016/j.clgc.2015.12.023. Epub 2015 Dec 24.
    • Plumbagin, a naphthaquinone derivative induces apoptosis in BRCA 1/2 defective castrate resistant prostate cancer cells as well as prostate cancer stem-like cells.
    • R S R, K H S, Somasundaram V, S SK, Nadhan R, Nair RS, Srinivas P.
    • Pharmacol Res. 2016 Mar;105:134-45. doi: 10.1016/j.phrs.2016.01.012. Epub 2016 Jan 22.
    • Caring for Patients With Prostate Cancer Who Are BRCA Positive.
    • Hartzfeld D, Berse B, Lowrance W, Dash A, Brawer M, Lawrence J, Meyer L, Lynch J.
    • Fed Pract. 2016 Feb;33(Suppl 1):46S-51S.
    • Prostate Cancer Gene Alterations Support Potential Role of PARP inhibitors.
    • Bryant Furlow.
    • OncoTherapy Network. 2016 Jan 15.
    • High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.
    • Castro E, Jugurnauth-Little S, Karlsson Q, Al-Shahrour F, Piñeiro-Yañez E, Van de Poll F, Leongamornlert D, Dadaev T, Govindasami K, Guy M, Eeles R, Kote-Jarai Z; UKGPCS, EMBRACE and IMPACT studies.
    • Ann Oncol. 2015 Nov;26(11):2293-300. doi: 10.1093/annonc/mdv356. Epub 2015 Sep 7.
    • Molecular landscape of prostate cancer: Implications for current clinical trials.
    • Khemlina G, Ikeda S, Kurzrock R.
    • Cancer Treat Rev. 2015 Nov;41(9):761-6. doi: 10.1016/j.ctrv.2015.07.001. Epub 2015 Jul 9.
    • DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
    • Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS.
    • N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859.

    Related:

    Third of men with treatment resistant prostate cancer respond to drug that targets gene defect, study finds

    Molecular stratification and repair defects: revealing hidden treasures.

    • Prolonged Survival in a Patient with a Pancreatic Acinar Cell Carcinoma.
    • Ploquin A, Baldini C, Vuagnat P, Makhloufi S, Desauw C, Hebbar M.
    • Case Rep Oncol. 2015 Oct 22;8(3):447-450. doi: 10.1159/000441414.
    • To BRCA or Not to PALB.
    • McNamara MG, Lamarca A, Hubner RA, Valle JW.
    • J Clin Oncol. 2015 Aug 10;33(23):2581-2. doi: 10.1200/JCO.2014.60.0585. Epub 2015 Jun 29.

    Related:

    Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

    Letter:

    Reply to M.G. McNamara et al and M.S. Copur et al.

    • Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.
    • Castro E, Goh C, Leongamornlert D, Saunders E, Tymrakiewicz M, Dadaev T, Govindasami K, Guy M, Ellis S, Frost D, Bancroft E, Cole T, Tischkowitz M, Kennedy MJ, Eason J, Brewer C, Evans DG, Davidson R, Eccles D, Porteous ME, Douglas F, Adlard J, Donaldson A, Antoniou AC, Kote-Jarai Z, Easton DF, Olmos D, Eeles R.
    • Eur Urol. 2015 Aug;68(2):186-93. doi: 10.1016/j.eururo.2014.10.022. Epub 2014 Nov 6.

    Related:

    Comment / Editorial:

    Clinical Management of Prostate Cancer in Men with BRCA Mutations.

    • Clinical Management of Prostate Cancer in Men with BRCA Mutations.
    • Bratt O, Loman N.
    • Eur Urol. 2015 Aug;68(2):194-5. doi: 10.1016/j.eururo.2014.11.005. Epub 2014 Nov 15.
    • Editorial / Commentary

    Related:

    Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.

    • Sequences and combinations of multifaceted therapy in advanced prostate cancer.
    • Vaishampayan UN.
    • Curr Opin Oncol. 2015 May;27(3):201-8. doi: 10.1097/CCO.0000000000000187.
    • Role of PARP-1 in prostate cancer.
    • Deshmukh D, Qiu Y.
    • Am J Clin Exp Urol. 2015 Apr 25;3(1):1-12. eCollection 2015.
    • Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    • Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM.
    • J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.

    Related:

    Comment / Letter:

    Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?

    Letter:

    To BRCA or Not to PALB.

    Letter:

    Reply to M.G. McNamara et al and M.S. Copur et al.

    Comment / Editorial:

    The Long and Winding Road.

    Press: Olaparib Trial Offers a Look at Precision Medicine's Future. (Medscape Oncology)

    • Olaparib effective in four advanced cancers.
    • [No authors listed]
    • Cancer Discov. 2015 Jan;5(1):OF3. doi: 10.1158/2159-8290.CD-NB2014-176. Epub 2014 Dec 9.
    • PCAT-1, a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer.
    • Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY.
    • Cancer Res. 2014 Mar 15;74(6):1651-60. doi: 10.1158/0008-5472.CAN-13-3159. Epub 2014 Jan 28.
    • Clinical features and management of BRCA1 and BRCA2-associated prostate cancer.
    • Alanee SR, Glogowski EA, Schrader KA, Eastham JA, Offit K.
    • Front Biosci (Elite Ed). 2014 Jan 1;6:15-30.
    • PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
    • Lee JM, Ledermann JA, Kohn EC.
    • Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384. Epub 2013 Nov 12.
    • The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    • Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM.
    • Lancet Oncol. 2013 Aug;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. Epub 2013 Jun 28.

    Related:

    Commentary:

    PARP inhibitors: pitfalls and promises.

    • Olaparib shows promise in multiple tumor types.
    • [No authors listed]
    • Cancer Discov. 2013 Jul;3(7):OF5. doi: 10.1158/2159-8290.CD-NB2013-082. Epub 2013 Jun 6.
    • Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer.
    • Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami K, Guy M, Sawyer E, Wilkinson R, Ardern-Jones A, Ellis S, Frost D, Peock S, Evans DG, Tischkowitz M, Cole T, Davidson R, Eccles D, Brewer C, Douglas F, Porteous ME, Donaldson A, Dorkins H, Izatt L, Cook J, Hodgson S, Kennedy MJ, Side LE, Eason J, Murray A, Antoniou AC, Easton DF, Kote-Jarai Z, Eeles R.
    • J Clin Oncol. 2013 May 10;31(14):1748-57. doi: 10.1200/JCO.2012.43.1882. Epub 2013 Apr 8.

    Related:

    Comment:

    Re: Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

    Research news:

    Patients with prostate cancer and BRCA2 mutations need urgent treatment.

    Press: Gene linked to more aggressive prostate cancer. (PHG Foundation)

    Press: First genetic factor in prostate cancer prognosis identified. (EurekAlert!)

    • Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.
    • Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, Yap TA, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J.
    • Ann Oncol. 2013 May;24(5):1416-8. doi: 10.1093/annonc/mdt074. Epub 2013 Mar 22.
    • Familial prostate cancer: the damage done and lessons learnt.
    • Taherian N, Hamel N, Bégin LR, Bismar TA, Goldgar DE, Feng BJ, Foulkes WD.
    • Nat Rev Urol. 2013 Feb;10(2):116-22. doi: 10.1038/nrurol.2012.257. Epub 2013 Jan 15.
    • High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
    • Willems-Jones A, Kavanagh L, Clouston D, Bolton D; kConFab Investigators, Fox S, Thorne H.
    • BJU Int. 2012 Dec;110(11 Pt C):E1181-6. doi: 10.1111/j.1464-410X.2012.11519.x. Epub 2012 Oct 4.
    • Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    • Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.
    • Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

    Related:

    Comment:

    Addicted to PAR? A closer look at PARP inhibitor sensitivity.

    Comment:

    Predicting PARP inhibitor sensitivity and resistance.

    • The role of BRCA1 and BRCA2 in prostate cancer.
    • Castro E, Eeles R.
    • Asian J Androl. 2012 May;14(3):409-14. doi: 10.1038/aja.2011.150. Epub 2012 Apr 23.
    • Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.
    • Gallagher DJ, Cronin AM, Milowsky MI, Morris MJ, Bhatia J, Scardino PT, Eastham JA, Offit K, Robson ME.
    • BJU Int. 2012 Mar;109(5):713-9. doi: 10.1111/j.1464-410X.2011.10292.x. Epub 2011 Jul 14.